Methods for treating TNFα-related disorders

A stable subcutaneous formulation of anti-TNFα antibodies addresses the inconvenience of intravenous administration by enabling self-administration, offering comparable efficacy and improved patient convenience.

JP7577674B2Active Publication Date: 2024-11-05CELLTRION INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021550084
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-28
Filing Date
2020-02-28
Publication Date
2024-11-05
Estimated Expiration
2040-02-28

AI Technical Summary

Technical Problem

Current intravenous administration of TNFα inhibitors like infliximab is inconvenient and burdensome for patients, requiring multiple visits to healthcare facilities and limiting administration to medically trained personnel, while a stable subcutaneous formulation is lacking.

Method used

Development of a stable subcutaneous formulation of anti-TNFα antibodies, such as infliximab, with specific components like polysorbate, sugars, and buffers, allowing for self-administration by patients after training, reducing administration time to minutes compared to hours for intravenous methods.

Benefits of technology

The subcutaneous formulation provides comparable efficacy and stability to intravenous administration, improving patient convenience and quality of life by allowing self-administration and reducing hospital visits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577674000026
    Figure 0007577674000026
  • Figure 0007577674000027
    Figure 0007577674000027
  • Figure 0007577674000028
    Figure 0007577674000028
Patent Text Reader

Abstract

The present invention relates to a method for treating TNFα-related diseases by subcutaneous administration of an antibody that binds to TNFα (anti-TNFα antibody) or an antigen-binding fragment thereof. The treatment method, composition, kit, or use of the present invention offers the advantage of improving patient satisfaction by improving convenience and quality of life, i.e., by reducing the time required for administration and shortening the patient's hospital stay compared to intravenous injection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to methods of treating TNFα-related diseases by subcutaneous administration of an antibody that binds to TNFα (an anti-TNFα antibody).

[0002] This application claims priority to Korean Patent Application No. 10-2019-0023769, filed on February 28, 2019, the entire contents of which are incorporated herein by reference. [Background technology]

[0003] Tumor necrosis factor alpha (TNFα) is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that form the acute phase response. TNFα is associated with a variety of diseases and disorders, including sepsis, infections, autoimmune diseases, and transplant rejection. TNFα stimulates the immune response and causes many clinical problems associated with autoimmune disorders, such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, pediatric Crohn's disease, psoriasis, and psoriatic arthritis. Such disorders can be treated with TNFα inhibitors.

[0004] Infliximab is a type of chimeric monoclonal antibody that can function as a TNFα inhibitor, and current commercially available infliximab products include Remsima, Remicade, Renflexis, etc. However, all of these products are prepared as lyophilized powders, which are reconstituted and diluted for intravenous injection according to the dosing schedule and dose selected for each disease.

[0005] However, the above-mentioned intravenous administration method requires the patient to visit a doctor for treatment, and takes 2 to 4 hours, including waiting time, which indicates that such a method brings about a considerable burden and inconvenience in daily life. Furthermore, there is a problem that the people who administer the drug are limited to those who have received medical education.

[0006] Subcutaneous (SC) administration has therefore been proposed as an alternative route of administration, which may allow patients to self-inject after training and may reduce the time required to 2-5 minutes compared to the 30-90 minutes required for intravenous administration in the prior art.

[0007] Commercially available formulations have been developed not only for intravenous administration but also for subcutaneous administration, including Rituxan (rituximab), Simponi (golimumab), Herceptin (trastuzumab), Actemra (tocilizumab), and Xolair (omalizumab), but a subcutaneous formulation of infliximab has not yet been reported.

[0008] For subcutaneous administration, a stable liquid formulation containing a high concentration of antibody is required, and its clinical efficacy and safety must be demonstrated.

[0009] The applicants have demonstrated that the CT-P13 formulation for subcutaneous administration has the same efficacy and stability as the conventional formulation for intravenous administration, thereby completing a subcutaneous administration therapy that is more useful for patients, more convenient to administer, and improves the quality of patients' lives. Summary of the Invention [Problem to be solved by the invention]

[0010] An object of the present invention is to provide a method of treatment for treating a TNFα-related disease, comprising subcutaneously administering to a subject a pharmaceutical composition comprising an anti-TNFα antibody or an antigen-binding fragment thereof.

[0011] Another object of the present invention is to provide a pharmaceutical composition for treating a disease treatable with an anti-TNFα antibody, said pharmaceutical composition comprising an anti-TNFα antibody or an antigen-binding fragment thereof, which is administered subcutaneously to a subject.

[0012] Yet another object of the present invention is to provide a kit comprising a pharmaceutical composition comprising an anti-TNFα antibody or an antigen-binding fragment thereof and instructions for administering said pharmaceutical composition subcutaneously to a subject to treat a disease treatable with an anti-TNFα antibody.

[0013] Yet another object of the present invention is to provide the use of an anti-TNFα antibody, or an antigen-binding fragment thereof, in the preparation of a medicament to be administered subcutaneously to a subject to treat a disease treatable with an anti-TNFα antibody. [Means for solving the problem]

[0014] The present invention provides a method for treating a disease treatable with an anti-TNFα antibody, comprising the step of subcutaneously administering to a subject a pharmaceutical composition comprising an anti-TNFα antibody or an antigen-binding fragment thereof.

[0015] The present invention also provides a pharmaceutical composition for treating a disease treatable with an anti-TNFα antibody, comprising an anti-TNFα antibody or an antigen-binding fragment thereof, which is administered subcutaneously to a subject.

[0016] The invention further provides a kit comprising (a) a pharmaceutical composition comprising an anti-TNFα antibody or antigen-binding fragment thereof, and a pharma- ceutically acceptable carrier, and (b) instructions for administering the pharmaceutical composition subcutaneously to a subject to treat a disease treatable with an anti-TNFα antibody.

[0017] The invention also provides the use of an anti-TNFα antibody, or an antigen-binding fragment thereof, in the preparation of a medicament for subcutaneous administration to a subject to treat a disease treatable with an anti-TNFα antibody.

[0018] In certain embodiments of the invention, the anti-TNFα antibody may comprise one or more selected from the group consisting of infliximab, adalimumab, certolizumab pegol, golimumab, and post-emulsion formulations thereof.

[0019] In one embodiment of the invention, the anti-TNFα antibody may be infliximab.

[0020] In certain embodiments of the invention, the anti-TNFα antibody may comprise a chimeric human-mouse IgG monoclonal antibody.

[0021] In one embodiment of the invention, the anti-TNFα antibody may comprise a light chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO:1, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:2, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:6.

[0022] In one embodiment of the invention, an anti-TNFα antibody may comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:7, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8.

[0023] In one embodiment of the invention, the anti-TNFα antibody may comprise a light chain comprising the amino acid sequence of SEQ ID NO:9 and a heavy chain comprising the amino acid sequence of SEQ ID NO:10.

[0024] In one embodiment of the invention, the composition may comprise a surfactant, a sugar or a derivative thereof, and a buffer comprising acetate or histidine.

[0025] In one embodiment of the invention, the composition may include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or mixtures thereof as a surfactant.

[0026] In one embodiment of the present invention, the concentration of the surfactant in the composition may be 0.02 to 0.1% (w / v).

[0027] In one embodiment of the invention, the composition may comprise, as sugar or a derivative thereof, sorbitol, mannitol, trehalose, sucrose, or a mixture thereof.

[0028] In one embodiment of the invention, the concentration of the sugar or its derivative in the composition may be 1-10% (w / v).

[0029] In one embodiment of the invention, the composition may include acetate as a buffering agent.

[0030] In one embodiment of the invention, the concentration of the buffer in the composition may be from 1 to 50 mM.

[0031] In one embodiment of the invention, the composition may have a pH of 4.0 to 5.5.

[0032] In one embodiment of the present invention, the composition may contain (A) 90 to 180 mg / ml of an anti-TNFα antibody, (B) 0.02 to 0.1% (w / v) of polysorbate, (C) 1 to 10% (w / v) of sorbitol, and (D) 1 to 50 mM of a buffer containing acetate or histidine.

[0033] In one embodiment of the invention, the composition may be free of aspartic acid, lysine, arginine, or mixtures thereof.

[0034] In some embodiments of the invention, the composition may be free of NaCl, KCl, NaF, KBr, NaBr, Na2SO4, NaSCN, K2SO4, or mixtures thereof.

[0035] In one embodiment of the invention, the composition may be free of a chelating agent.

[0036] In one embodiment of the invention, the composition may have a viscosity of 0.5 to 10.0 cp after storage for 1 month at a temperature of 40±2° C., or a viscosity of 0.5 to 5.0 cp after storage for 6 months at a temperature of 5±3° C.

[0037] In certain embodiments of the invention, the composition does not need to undergo a reconstitution step, a dilution step, or both, prior to use.

[0038] In one embodiment of the invention, the composition may be loaded into a pre-filled syringe or auto-injector prior to administration to a subject.

[0039] In certain embodiments of the invention, the subject may include a mammal.

[0040] In certain embodiments of the invention, the subject may include a human.

[0041] In one embodiment of the invention, the antibody or antigenic fragment thereof may be administered in a dose of 60-300 mg.

[0042] In certain embodiments of the invention, diseases treatable with anti-TNFα antibodies may include rheumatoid arthritis, ulcerative colitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

[0043] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at a dose of 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, or 300 mg.

[0044] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at a dose of 90-300 mg.

[0045] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at a dose of 90-180 mg.

[0046] In some embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at a dose of 120 to 240 mg. In some embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at a dose of 80 to 100 mg, 110 to 130 mg, 170 to 190 mg, or 230 to 250 mg.

[0047] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered in a dose of 90 mg, 120 mg, 180 mg, or 240 mg.

[0048] In one embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered to a subject at a dose of 90-180 mg when the TNFα-related disease is rheumatoid arthritis.

[0049] In certain embodiments of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered to a subject at a dose of 90 mg, 120 mg, or 180 mg when the TNFα-related disease is rheumatoid arthritis.

[0050] In one embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered to a subject at a dose of 120 to 240 mg when the TNFα-related disease is one or more selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis.

[0051] In certain embodiments of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered to a subject at a dose of 120 mg, 150 mg, 180 mg, or 240 mg when the TNFα-related disease is one or more selected from the group consisting of ulcerative colitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at increasing doses depending on the subject's condition.

[0052] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at a dose of 90-180 mg if the subject weighs less than 80 kg, or at a dose of 190-270 mg if the subject weighs 80 kg or more.

[0053] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at intervals of 1 to 8 weeks.

[0054] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at intervals of 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks.

[0055] In certain embodiments of the invention, the antibody or antigen-binding fragment thereof may be administered at two-week or four-week intervals.

[0056] In one embodiment of the invention, the patient to whom the anti-TNFα antibody is administered is: (a) Patients who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate; (b) patients who have not been previously treated with methotrexate and other DMARDs; (c) Patients who exhibit severe axial symptoms that do not respond adequately to conventional treatment and elevated serologic indicators associated with inflammation, or (d) Patients who are unresponsive to, contraindicated to, or intolerant to systemic treatment including methotrexate, cyclosporine, or cutaneous photochemotherapy (psoralen ultraviolet A therapy: PUVA) (e) Patients who have had an inadequate response to treatment with corticosteroids, 6-mercaptopurine, azathioprine, or immunosuppressants, patients who are intolerant to such treatment, or patients for whom such treatment is contraindicated, or (f) Patients who do not respond to standard treatments, including antibiotic therapy, excretion therapy, or immunosuppressive therapy. The present invention may exhibit one or more characteristics selected from the following:

[0057] In certain embodiments of the invention, the patient may have received at least one intravenous dose of an anti-TNFα antibody or antigen-binding fragment thereof prior to subcutaneous administration.

[0058] In certain embodiments of the invention, the patient may have received at least two or three intravenous doses of an anti-TNFα antibody or antigen-binding fragment thereof prior to subcutaneous administration.

[0059] In one embodiment of the present invention, (a) a patient with rheumatoid arthritis may be a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously two times prior to subcutaneous administration, and (b) a patient with one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis may be a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously two or three times prior to subcutaneous administration.

[0060] In one embodiment of the invention, the patient may have received two intravenous doses of an anti-TNFα antibody or antigen-binding fragment thereof at weeks 0 and 2 prior to subcutaneous administration, or may have received three intravenous doses of an anti-TNFα antibody or antigen-binding fragment thereof at weeks 0, 2, and 6.

[0061] In certain embodiments of the invention, the patient may have received at least one intravenous dose of an anti-TNFα antibody or antigen-binding fragment thereof prior to the subcutaneous administration.

[0062] In one embodiment of the present invention, the patient may have received an anti-TNFα antibody or an antigen-binding fragment thereof intravenously at a dose of 1 to 10 mg / kg per administration prior to subcutaneous administration.

[0063] In one embodiment of the present invention, the patient may have received an anti-TNFα antibody or an antigen-binding fragment thereof intravenously at a dose of 3 to 5 mg / kg per administration prior to subcutaneous administration.

[0064] In one embodiment of the present invention, (a) a patient having rheumatoid arthritis may be a patient to whom an anti-TNFα antibody or an antigen-binding fragment thereof is administered intravenously at a dose of 3 mg / kg per administration, and (b) a patient having one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis may be a patient to whom an anti-TNFα antibody or an antigen-binding fragment thereof is administered intravenously at a dose of 5 mg / kg per administration.

[0065] In one embodiment of the invention, the first subcutaneous administration may occur 2-8 weeks after the last intravenous administration.

[0066] In one embodiment of the invention, the first subcutaneous administration may occur four weeks after the last intravenous administration.

[0067] In certain embodiments of the invention, a composition comprising an anti-TNFα antibody or antigen-binding fragment thereof may be administered simultaneously with, prior to, or following administration of one or more selected from the group consisting of infliximab, adalimumab, certolizumab pegol, golimumab, and derivatives thereof.

[0068] In certain embodiments of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered simultaneously with, prior to, or subsequent to administration of one or more selected from the group consisting of anti-rheumatic drugs (DMARDs), steroids, and immunosuppressants. Specifically, the disease-modifying anti-rheumatic drugs (DMARDs) may be selected from the group consisting of methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine, the steroids may be selected from the group consisting of corticosteroids, glucocorticoids, cortisol, mineralocorticoids, and aldosterone, and the immunosuppressants may be selected from the group consisting of azathioprine, 6-mercaptopurine, cyclosporine A, tacrolimus, mycophenolic acid, bredinin, mTOR inhibitors, and antilymphocyte antibodies.

[0069] In one embodiment of the invention, the minimum serum concentration (C トラフ A method of administration may be provided in which the concentration (the minimum concentration immediately before the next application) is maintained at 0.01 μg / ml or more after subcutaneous administration to a patient.

[0070] In one embodiment of the invention, the present invention relates to a method for determining the minimum serum concentration (C ) of an anti-TNFα antibody or antigen-binding fragment thereof for a patient with rheumatoid arthritis. トラフ) is maintained at 1 μg / ml or more, and (b) for patients with one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, the minimum serum concentration (C トラフ A method of administration may be provided in which the concentration of the IgG4 antibody is maintained at 5 μg / ml or higher.

[0071] In one embodiment of the invention, the patient after subcutaneous administration: (a) a reduction in DAS28 (Disease Activity Score in 28 joints) of at least 2.0; or (b) A decrease of at least 70 in the Crohn's Disease Activity Index (CDAI) The present invention may exhibit one or more of the following characteristics: Effect of the Invention

[0072] The treatment method, composition, kit, or use of the present invention allows the treatment of TNFα-related diseases by subcutaneous administration of an anti-TNFα antibody or an antigen-binding fragment thereof. Furthermore, the treatment method, composition, kit, or use of the present invention offers the advantage of improving patient satisfaction by improving convenience and quality of life, i.e., by reducing the time required for administration and reducing the length of hospital stay of patients, compared to intravenous administration.

[0073] Furthermore, the treatment method, composition, kit, or use of the present invention is added as a new treatment option for infliximab, and as a result, it provides the advantage of eliminating the burden and rejection caused by drug changes not only for medical professionals but also for patients who have been administered infliximab by conventional intravenous administration. [Brief description of the drawings]

[0074] [Figure 1]1A-C are simulation graphs showing mean (±SD) blood infliximab concentrations over time in patients with CD in Study 1.6 Part 1 (A: cohort receiving 120 mg SC, B: cohort receiving 180 mg SC, and C: cohort receiving 240 mg SC) receiving infliximab (IV or SC). [Diagram 2] FIG. 1 is a simulation graph showing median infliximab blood concentrations over time at steady state in patients with inflammatory bowel disease (IBD) administered 120 mg infliximab SC or infliximab IV in Study 1.6 Part 2. [Diagram 3] FIG. 1 is a graph showing the 54-week pharmacokinetic profiles between SC and IV dosage forms of infliximab (◯: SC dosage form, and △: IV dosage form). [Figure 4] 13A-B are simulated graphs showing median values ​​over time for infliximab SC administered every 2 weeks starting at week 0 without infliximab IV. A: Simulated plasma concentration of infliximab over time for each experimental cohort (solid line: cohort administered 2 doses of 3 mg / kg IV followed by 120 mg SC, and dotted line: cohort administered 120 mg SC); and B: Simulated DAS28 over time for each experimental cohort. [Diagram 5] Graphs showing box plots of (A) nadir serum concentration (C trough) and (B) DAS28 scores at weeks 2, 6, and 14 for each experimental group (gray boxes: group receiving 120 mg SC after two IV doses, and red boxes: group receiving 120 mg SC). [Figure 6] FIG. 1 is a graph showing the 54-week pharmacokinetic profiles between IV and SC dosage forms of infliximab (●: SC dosage form, and △: IV dosage form). [Figure 7] FIG. 13 is a graph comparing the observed CDAI scores (denoted by circles) and the model-predicted CDAI scores (solid black line) as a result of the VPC obtained from the final PK-PD model. [Figure 8] FIG. 13 shows simulated data for mean plasma concentrations over time for each dosing regimen from week 10 onwards following administration of 5 mg / kg IV to CD patients at weeks 0, 2, and 6. [Figure 9] FIG. 13 is a graph showing simulated data for CD patients for CDAI score over time for each dosing regimen from week 10 onwards following administration of 5 mg / kg IV at weeks 0, 2 and 6. [Figure 10] FIG. 13 is a graph showing simulated data for UC patients for mean plasma concentrations over time for each dosing regimen from week 10 onwards following administration of 5 mg / kg IV at weeks 0, 2, and 6. [Figure 11] 1 is a graph showing simulated data for UC patients for Mayo score over time for each dosing regimen from week 10 onwards following administration of 5 mg / kg IV at weeks 0, 2 and 6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0075] The present invention relates to a method of treating a disease treatable with an anti-TNFα antibody, comprising the step of subcutaneously administering to a subject a pharmaceutical composition comprising an anti-TNFα antibody or an antigen-binding fragment thereof.

[0076] To facilitate understanding of the present invention, the terms used herein are defined as follows.

[0077] "TNFα" is intended to refer to a human cytokine that exists as a 17 kD secreted form and a 26 kD membrane-bound form, the biologically active form of TNFα consisting of a trimer non-covalently linked to the 17 kD molecule. The structure of TNFα is further described in the literature, for example, see Pennica, D., et al. (1984) Nature 312:724-729; Davis, JM, et al. (1987) Biochemistry 26:1322-1326; and Jones, EY, et al. (1989) Nature 338:225-228.

[0078] The term "antibody" refers to an immunoglobulin molecule consisting of four polypeptide chains, two heavy and two light chains inter-connected by disulfide bonds. Other naturally occurring antibodies with modified structures, such as camelized antibodies, are also included in this definition. Each heavy chain consists of a heavy chain variable region and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region and a light chain constant region. The light chain constant region consists of one domain (CL). The heavy and light chain variable regions can be further divided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). The heavy and light chain variable regions each consist of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0079] The term "antigen-binding fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to the antigen bound by the intact antibody. Exemplary antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv.

[0080] The term "follow-on product" refers to a biological product that is so similar to an FDA-approved biological product (the "target drug") that it has no clinically meaningful differences from the target drug in terms of pharmacokinetics, safety, and efficacy.

[0081] The term "biological dosage form" or "biological product" refers to a pharmaceutical product that is prepared using raw materials or substances derived from humans or other living organisms and that requires special public health attention, including biological products, recombinant DNA products, cell culture-derived products, cell therapy products, gene therapy products, and other preparations approved by the Ministry of Food and Drug Safety.

[0082] The term "administration" refers to the administration of a substance (eg, an anti-TNFα antibody) to achieve a therapeutic goal (eg, a TNFα-related disorder).

[0083] The term "TNFα-related disease" refers to a local / systemic physiological disease in which TNFα is a major mediator leading to disease symptoms. As used herein, the terms "TNFα-related disease," "TNFα-treatable disease," and "disease in which TNFα activity is detrimental" are used interchangeably.

[0084] The term "subject" includes both human and non-human animals. The term "non-human animals" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, cats, rabbits, and ferrets, rodents such as mice, rats, and guinea pigs, birds such as chickens, amphibians, and reptiles. In preferred embodiment aspects, the subject is a mammal such as a non-human primate, sheep, dog, cat, rabbit, ferret, or rodent. In more preferred embodiment aspects, the subject is a human. As used herein, the terms "subject," "patient," and "individual" are used interchangeably.

[0085] "I C 50 The term "concentration of inhibitor" is intended to refer to the concentration of inhibitor required to inhibit a desired biological outcome, e.g., to neutralize cytotoxic activity.

[0086] “Minimum serum concentration (C トラフ The term "model-predicted trough serum concentration" is an abbreviation for model-predicted trough serum concentration and means the lowest concentration of a drug in the blood predicted using a population pharmacokinetic model.

[0087] The term "DAS28 (Disease Activity Score in 28 joints)" refers to a method of assessing disease activity in rheumatoid arthritis (RA) using 28 joints.

[0088] The term "CDAI (Crohn's Disease Activity Index)" refers to a testing tool used to quantify symptoms in patients with Crohn's disease.

[0089] The term "antirheumatic drugs (disease-modifying antirheumatic drugs, DMARDs)" refers to a combination of oral drugs that are effective in reducing the symptoms of arthritis and slowing the progression of the disease. DMARDs prevent the immune system from having the effect of releasing chemicals that attack the joints and damage bones, tendons, ligaments, or cartilage. Specific classes of DMARD-based drugs include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide.

[0090] The term "kit" refers to a packaged commercial product containing components for administering a TNFα antibody of the invention to treat a TNFα-related disorder. The kit preferably includes a container or box for holding the components of the kit. The box or container bears a label or protocol approved by the Food and Drug Administration. The box or container holds the components of the invention contained in a plastic, polyethylene, polypropylene, ethylene, or propylene container. The container may be a tube or bottle with a lid. The kit also includes instructions for administering the TNFα antibody of the invention.

[0091] Various aspects of the invention will now be described in further detail.

[0092] The anti-TNFα antibody or antigen-binding fragment thereof of the present invention In some embodiments of the invention, the antibody may comprise a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a single chain antibody, a hybrid antibody, a chimeric antibody, a humanized antibody, or a fragment thereof. The term "chimeric antibody" refers to an antibody that comprises heavy and light chain variable region sequences from one species and constant region sequences from another species. In some embodiments of the invention, the antibody may comprise a chimeric human-mouse IgG monoclonal antibody. A chimeric human-mouse IgG monoclonal antibody is composed of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. A chimeric human-mouse IgG monoclonal antibody may be prepared by methods well known to those skilled in the art. For example, infliximab may be prepared by methods described in U.S. Pat. No. 6,284,471.

[0093] In some embodiments of the invention, the antibody may comprise an antibody that binds to TNFα or an epitope of TNFα. The antibody that binds to TNFα or an epitope of TNFα may comprise one or more selected from the group consisting of infliximab, adalimumab, certolizumab pegol, golimumab, and derivatives thereof. In some embodiments of the invention, the antibody may comprise infliximab.

[0094] In one embodiment of the invention, the antibody or antigen-binding fragment thereof may comprise a light chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 6.

[0095] In one embodiment of the invention, the antibody or antigen-binding fragment thereof may comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:7, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8.

[0096] In one embodiment of the invention, the antibody may comprise a light chain comprising the amino acid sequence of SEQ ID NO:9 and a heavy chain comprising the amino acid sequence of SEQ ID NO:10.

[0097] Compositions comprising the anti-TNFα antibody of the present invention or antigen-binding fragments thereof As used herein, the term "a composition comprising an anti-TNFα antibody or antigen-binding fragment thereof of the present invention" is used interchangeably with "stable liquid pharmaceutical formulation."

[0098] The composition of the present invention comprises (A) an antibody or an antigen-binding fragment thereof, (B) a surfactant, (C) a sugar or a derivative thereof, and (D) a buffering agent.

[0099] As used herein, the term "free of" means that the component is not contained at all. Furthermore, the term means that the component is substantially not contained at all, i.e., the component is contained within an amount that does not affect the activity of the antibody and the stability and viscosity of the liquid pharmaceutical formulation. For example, the term means that the component is contained in an amount of 0-1% (w / v), 0-1 ppm (w / v), or 0-1 ppb (w / v) relative to the total weight of the liquid pharmaceutical formulation.

[0100] (A) An antibody or an antigen-binding fragment thereof In certain embodiments, a composition of the invention may comprise an anti-TNFα antibody or antigen-binding fragment thereof of the invention, as described in detail above.

[0101] The concentration of the antibody or antigen-binding fragment thereof may be freely adjusted within a range that does not substantially adversely affect the stability and viscosity of the composition of the present invention. In one embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 10 to 200 mg / ml. In another embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 50 to 200 mg / ml. In yet another embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 80 to 200 mg / ml. In yet another embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 90 to 180 mg / ml. In yet another embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 90 to 145 mg / ml. In yet another embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 110 to 130 mg / ml. When the concentration of the antibody or antigen-binding fragment thereof is within the above range, the degree of freedom of the administration dose and administration cycle may be increased according to the high concentration of the antibody or antigen-binding fragment thereof, and excellent long-term stability and low viscosity may be exhibited.

[0102] (B) Surfactant Examples of surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters (e.g., polysorbates), polyoxyethylene alkyl ethers (e.g., Brij), alkylphenyl polyoxyethylene ethers (e.g., Triton X), polyoxyethylene-polyoxypropylene copolymers (e.g., poloxamer, Pluronic), sodium dodecyl sulfate (SDS), and the like.

[0103] In one embodiment of the invention, the surfactant may comprise a polyoxyethylene sorbitan fatty acid ester (polysorbate). The polysorbate may comprise polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a mixture of two or more thereof. In one embodiment of the invention, the polysorbate may comprise polysorbate 20, polysorbate 80, or a mixture thereof. In another embodiment of the invention, the polysorbate may comprise polysorbate 80.

[0104] In one embodiment of the present invention, the concentration of the surfactant may be freely adjusted within a range that does not adversely affect the stability and viscosity of the stable liquid pharmaceutical formulation of the present invention. For example, the concentration of the surfactant may be 0.001-5% (w / v), 0.01-1% (w / v), or 0.02-0.1% (w / v). When the concentration of the surfactant is within the above range, excellent long-term stability and low viscosity can be exhibited.

[0105] (C) Sugar or its derivatives The sugar may include monosaccharides, disaccharides, oligosaccharides, polysaccharides, or a mixture of two or more thereof. Examples of monosaccharides include, but are not limited to, glucose, fructose, galactose, etc. Examples of disaccharides include, but are not limited to, sucrose, lactose, maltose, trehalose, etc. Examples of oligosaccharides include, but are not limited to, fructooligosaccharides, galactooligosaccharides, mannanoligosaccharides, etc. Examples of polysaccharides include, but are not limited to, starch, glycogen, cellulose, chitin, pectin, etc.

[0106] The sugar derivative may include a sugar alcohol, a sugar acid, or a mixture thereof. Examples of sugar alcohols include, but are not limited to, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, polyglycitol, and the like. Examples of sugar acids include, but are not limited to, aldonic acids (such as glyceric acid), urosonic acids (such as neuraminic acid), uronic acids (such as glucuronic acid), aldaric acids (such as tartaric acid), and the like.

[0107] In certain embodiments of the invention, the sugar or derivative thereof may comprise sorbitol, mannitol, trehalose, sucrose, or a mixture of two or more thereof.

[0108] In one embodiment of the present invention, the concentration of the sugar or its derivative may be freely adjusted within a range that does not substantially adversely affect the stability and viscosity of the liquid pharmaceutical formulation of the present invention. For example, the concentration of the sugar or its derivative may be 0.1-30% (w / v), 1-20% (w / v), or 1-10% (w / v). When the concentration of the sugar or its derivative is within the above range, excellent long-term stability and low viscosity can be exhibited.

[0109] (D) Buffer A buffer is a neutralizing agent that minimizes changes in pH caused by acid or alkali. Examples of buffers include, but are not limited to, phosphate, acetate, succinate, gluconate, glutamate, citrate, histidine, and the like. In some embodiments of the present invention, the buffer may contain acetate or histidine. If the buffer contains both acetate and histidine, stability may be reduced.

[0110] In some embodiments of the present invention, the buffer may contain acetate. Examples of acetate include, but are not limited to, sodium acetate, zinc acetate, aluminum acetate, ammonium acetate, potassium acetate, etc. For pH adjustment, the buffer may further contain acid, such as acetic acid. It may be most preferable to contain acetic acid as a buffer in terms of pH adjustment and stability.

[0111] In one embodiment of the present invention, the buffering agent may include histidine. When histidine is used as the buffering agent, it may include a histidine salt, such as histidine hydrochloride, histidine acetate, histidine phosphate, histidine sulfate, etc. For pH adjustment, the buffering agent may include an acid, such as hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid, etc.

[0112] In certain embodiments of the present invention, the stable liquid pharmaceutical formulation may be free of citric acid, phosphate salts, or mixtures thereof.

[0113] In some embodiments of the present invention, the content of the buffering agent (or the anion of the buffering agent) may be freely adjusted within a range that does not substantially adversely affect the stability and viscosity of the liquid pharmaceutical formulation of the present invention. For example, the content of the buffering agent or its anion may be 1 to 50 mM, 5 to 30 mM, or 10 to 25 mM. When the content of the buffering agent or its anion is within the above range, excellent long-term stability and low viscosity can be exhibited.

[0114] (E) pH In some embodiments of the present invention, the pH of the stable liquid pharmaceutical composition may be 4.0 to 5.5, or 4.7 to 5.3. When the pH is within the above range, excellent long-term stability and low viscosity may be exhibited. The pH may be adjusted using a buffering agent. That is, when a buffering agent is included at a predetermined content, the pH may exhibit the above range without the need for a separate pH adjusting agent. When citric acid, phosphate salts, or a mixture thereof is used as a buffering agent, it may be difficult to exhibit a pH in the above range. When an acid (e.g., hydrochloric acid) or a base (e.g., sodium hydroxide) is further included as a separate pH adjusting agent, the stability of the antibody may be reduced.

[0115] (F) Other components In some embodiments of the present invention, the stable liquid pharmaceutical formulation may not contain aspartic acid, lysine, arginine, or a mixture thereof. When these amino acids are contained, such a formulation is in a solid state. In some embodiments of the present invention, the stable liquid pharmaceutical formulation may contain one or more amino acids other than the above three types of amino acids. In this case, the amino acids may be contained in a range of 5% (w / v) or less, for example, in a range of 0.001 to 5% (w / v), a range of 0.001 to 1% (w / v), a range of 0.01 to 5% (w / v), a range of 0.01 to 1% (w / v), a range of 0.1 to 5% (w / v), or a range of 0.1 to 1% (w / v).

[0116] In another embodiment of the present invention, the stable liquid pharmaceutical formulation may contain taurine, in which case taurine may be contained in a range of 5% (w / v) or less, for example, in the range of 0.001 to 5% (w / v), the range of 0.001 to 1% (w / v), the range of 0.01 to 5% (w / v), the range of 0.01 to 1% (w / v), the range of 0.1 to 5% (w / v), or the range of 0.1 to 1% (w / v).

[0117] In another embodiment of the present invention, the stable liquid pharmaceutical formulation may be free of metal salts such as NaCl, KCl, NaF, KBr, NaBr, Na2SO4, NaSCN, K2SO4, etc. If these metal salts are present, the formulation may experience precipitation phenomena and may have a gelatinous form and may be less stable.

[0118] In some embodiments of the present invention, the stable liquid pharmaceutical formulation may be free of chelating agents (e.g., EDTA), which may increase the rate of oxidation.

[0119] In some embodiments of the present invention, the stable liquid pharmaceutical formulation may be free of preservatives. Examples of preservatives include octadecyldimethylbenzylammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, benzyl alcohol, alkyl parabens, catechol, resorcinol, cyclohexanol, 3-pentanol, m-cresol, etc. If a preservative is included, it may not be useful for improving the stability of the pharmaceutical formulation.

[0120] In one embodiment of the present invention, the stable liquid pharmaceutical formulation of the present invention may further contain additives well known in the art within the scope of not substantially adversely affecting the activity of the antibody and the stability and low viscosity of the formulation. For example, such pharmaceutical formulations may further contain an aqueous carrier, an antioxidant, or a mixture of two or more of these. The aqueous carrier is a carrier that is pharma- ceutical acceptable (safe and non-toxic when administered to humans) and useful for preparing the liquid pharmaceutical formulation. Examples of aqueous carriers include, but are not limited to, sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), sterile saline, Ringer's solution, glucose, etc. Examples of antioxidants include, but are not limited to, ascorbic acid, etc.

[0121] (G) "Stable" Liquid Pharmaceutical Formulations In the context of a "stable" liquid pharmaceutical formulation of the invention, the term "stable" means that the antibody of the invention substantially retains its physical stability, and / or chemical stability, and / or biological activity during the production process and / or during storage / preservation. A variety of analytical techniques for measuring antibody stability are readily available in the art.

[0122] Physical stability can be assessed by methods known in the art, including the apparent light attenuation (absorbance or optical density) of a sample. Such light attenuation measurements are related to the turbidity of the formulation. Additionally, physical stability can be measured by the content of high molecular weight components, the content of low molecular weight components, the amount of intact protein, the number of sub-visible particles, etc.

[0123] Chemical stability can be evaluated, for example, by detecting and quantifying chemically altered forms of the antibody. Chemical stability can include, for example, charge changes (e.g., resulting from deamidation or oxidation), and can be evaluated, for example, by ion exchange chromatography. Chemical stability can be measured, for example, by charge variants (acidic or basic peaks).

[0124] Biological activity can be assessed by methods known in the art, for example, antigen-binding affinity can be measured by ELISA.

[0125] In certain embodiments of the present invention, the liquid pharmaceutical formulation may be stable for extended periods of time.

[0126] In certain embodiments of the present invention, the term "stable" liquid pharmaceutical formulation refers to a liquid pharmaceutical formulation that meets one or more of the following:

[0127] Turbidity A liquid pharmaceutical preparation whose absorbance (A600) measured by a spectrophotometer after storage for 4 weeks at a temperature of 40±2°C is 0 to 0.0300 or 0 to 0.0700. A liquid pharmaceutical formulation that has an absorbance (A600) of 0-0.0300 or 0-0.0700 measured by a spectrophotometer after storage for 4 weeks under closed conditions at a temperature of 40±2°C and a relative humidity of 75±5%.

[0128] Content of major components (major peaks) A liquid pharmaceutical preparation with a content of major components of 98-100% as measured by SE-HPLC after storage for 4 weeks at a temperature of 40±2℃ A liquid pharmaceutical preparation whose main component content is 98-100% as measured by SE-HPLC after storage for 4 weeks under closed conditions at a temperature of 40±2°C and a relative humidity of 75±5%.

[0129] Content of high molecular weight components (whose retention time peak is earlier than that of the main peak (intact IgG)) A liquid pharmaceutical formulation having a high molecular weight component content of 0-1.00% as measured by SE-HPLC after 12 months storage at a temperature of 5±3℃ Liquid pharmaceutical preparations with a high molecular weight component content of 0-1.00% as measured by SE-HPLC after 12 months of storage at 5±3℃ under closed conditions.

[0130] Content of low molecular weight components (whose retention time peak is later than that of the main peak (intact IgG)) A liquid pharmaceutical formulation having a low molecular weight component content of 0-0.40% as measured by SE-HPLC after 12 months of storage at a temperature of 5±3°C. Liquid pharmaceutical preparations with a low molecular weight component content of 0-0.40% as measured by SE-HPLC after 12 months of storage at 5±3°C under closed conditions.

[0131] Intact immunoglobulin G content A liquid pharmaceutical preparation having an intact immunoglobulin G content (intact IgG%) of 94.0-100% as measured by non-reduced CE-SDS after 12 months of storage at a temperature of 5±3°C. Liquid pharmaceutical preparations having an intact immunoglobulin G content (intact IgG%) of 94.0-100% as measured by non-reduced CE-SDS after 12 months of storage at 5±3°C under closed conditions. A liquid pharmaceutical preparation having an intact immunoglobulin G content (intact IgG%) of 94.0-100% as measured by non-reduced CE-SDS after storage for 4 weeks at a temperature of 40±2°C. Liquid pharmaceutical preparations having an intact immunoglobulin G content (intact IgG%) of 94.0-100% as measured by non-reduced CE-SDS after storage for 4 weeks under closed conditions at a temperature of 40±2°C and a relative humidity of 75±5%.

[0132] Intact heavy and light chain content A liquid pharmaceutical formulation having an intact heavy and light chain content (intact HC+LC%) of 99.0-100% as measured by reduced CE-SDS after 12 months of storage at a temperature of 5±3°C. Liquid pharmaceutical formulations with intact heavy and light chain content (intact HC+LC%) of 99.0-100% as measured by reduced CE-SDS after 12 months of storage at 5±3°C under closed conditions. A liquid pharmaceutical formulation having an intact heavy and light chain content (intact HC+LC%) of 98.0-100% as measured by reduced CE-SDS after storage for 4 weeks at a temperature of 40±2°C. Liquid pharmaceutical formulations having an intact heavy and light chain content (intact HC+LC%) of 98.0-100% as measured by reduced CE-SDS after storage for 4 weeks at a temperature of 40±2°C and a relative humidity of 75±5% under closed conditions.

[0133] Number of subvisible particles - Liquid pharmaceutical preparations with a subvisible particle count (10.00μ or more, less than 400.00μm) of 0-1,000 as measured by HIAC after 12 months of storage at 5±3℃ Liquid pharmaceutical preparations with a subvisible particle count (10.00μ or more, less than 400.00μm) of 0-1,000 as measured by HIAC after 12 months of storage at 5±3℃ under closed conditions. A liquid pharmaceutical preparation with a subvisible particle count (1.00μ or more, less than 100.00μm) of 0 to 30,000 as measured by MFI after storage for 4 weeks at a temperature of 40±2℃ A liquid pharmaceutical formulation having a number of subvisible particles (1.00μ or more and less than 100.00μm) of 0 to 30,000 as measured by MFI after storage for 4 weeks under closed conditions at a temperature of 40±2℃ and a relative humidity of 75±5%. A liquid pharmaceutical preparation with a subvisible particle count (10.00μ or more, less than 100.00μm) of 0-200 as measured by MFI after storage for 4 weeks at a temperature of 40±2℃ A liquid pharmaceutical formulation that has a subvisible particle count (10.00μ or more, less than 100.00μm) of 0-200 as measured by MFI after storage for 4 weeks under closed conditions at a temperature of 40±2℃ and a relative humidity of 75±5%. A liquid pharmaceutical preparation with a subvisible particle count (10.00μ or more, less than 100.00μm) of 0 to 500 as measured by MFI after storage for 6 weeks at a temperature of 40±2℃ A liquid pharmaceutical formulation that has a subvisible particle count (10.00μ or more, less than 100.00μm) of 0-500 as measured by MFI after storage for 6 weeks under closed conditions at a temperature of 40±2℃ and a relative humidity of 75±5%.

[0134] oxidation rate A liquid pharmaceutical formulation with an oxidation rate of heavy chain Met255 of 0-2.5% as measured by LC-MS after storage for 4 weeks at a temperature of 40±2°C Liquid pharmaceutical formulations with an oxidation rate of heavy chain Met255 of 0-2.5% as measured by LC-MS after storage for 4 weeks under closed conditions at a temperature of 40±2°C and a relative humidity of 75±5%.

[0135] Charge variants A liquid pharmaceutical preparation with an acidic peak of 20-35% as measured by IEC-HPLC after storage for 4 weeks at a temperature of 40±2℃ Liquid pharmaceutical preparations with an acidic peak of 20-35% as measured by IEC-HPLC after storage for 4 weeks under closed conditions at a temperature of 40±2°C and a relative humidity of 75±5%. A liquid pharmaceutical preparation with a basic peak of 33-40% as measured by IEC-HPLC after storage for 4 weeks at a temperature of 40±2℃ A liquid pharmaceutical preparation that has a basicity peak of 33-40% as measured by IEC-HPLC after storage for 4 weeks under closed conditions at a temperature of 40±2°C and a relative humidity of 75±5%.

[0136] TNFα binding affinity A liquid pharmaceutical formulation with a TNFα binding affinity of 80-120% as measured by ELISA after 12 months of storage at a temperature of 5±3°C A liquid pharmaceutical formulation with a TNFα binding affinity of 80-120% as measured by ELISA after 12 months of storage at 5±3°C under closed conditions.

[0137] In one embodiment of the invention, the pharmaceutical formulation may have a viscosity of 0.5-10.0 cp measured after one month of storage at a temperature of 40±2° C. In another embodiment of the invention, the pharmaceutical formulation may have a viscosity of 0.5-5.0 cp measured after six months of storage at a temperature of 5±3° C.

[0138] (H) Method for preparing stable liquid pharmaceutical formulations The stable liquid pharmaceutical formulation of the present invention may be prepared using a known method without being limited to a specific method. For example, the liquid pharmaceutical formulation may be prepared by adding a buffer to a solution containing a surfactant and a sugar or a derivative thereof while adjusting the pH of the solution, and then adding an antibody to the resulting mixed solution. Furthermore, the liquid pharmaceutical formulation may be prepared by preparing a solution containing some non-active excipient in the final step of the purification process, and then adding the remaining components to the solution. For example, the liquid pharmaceutical formulation may be prepared by preparing a solution containing an antibody, a buffer, and a sugar or a derivative thereof in the final step of the purification process, and then adding a surfactant to the solution.

[0139] Furthermore, the method of preparation of the formulation may or may not include a freeze-drying process.

[0140] Where such preparation methods do not include a freeze-drying process, for example, the liquid pharmaceutical formulations of the present invention may be prepared, then treated by a sterilization method or the like, and immediately placed into a sealed container.

[0141] When such preparation method includes a freeze-drying process, for example, the liquid pharmaceutical formulation of the present invention may be prepared and freeze-dried, or the liquid pharmaceutical formulation of the present invention may be prepared and then freeze-dried and stored / preserved, and then the components removed or altered by such freeze-drying and / or storage / preservation may be supplemented or replaced, thereby preparing the liquid pharmaceutical formulation of the present invention. Alternatively, the components of the liquid pharmaceutical formulation of the present invention excluding the components that may be removed or altered by freeze-drying and / or storage / preservation may be freeze-dried, or such components may be freeze-dried and stored / preserved, and then the components removed above may be added thereto, thereby preparing the liquid pharmaceutical formulation of the present invention.

[0142] Korean Patent Application Nos. 10-2017-0081814 and 10-2018-0102233 previously filed by the present applicants are hereby incorporated by reference.

[0143] Methods for treating diseases treatable with the anti-TNFα antibodies of the present invention The present invention provides a method for treating a disease treatable with anti-TNFα, comprising the step of subcutaneously administering to a subject a pharmaceutical composition comprising an anti-TNFα antibody or an antigen-binding fragment thereof.

[0144] In certain embodiments of the invention, the antibody may comprise one or more selected from the group consisting of infliximab, adalimumab, certolizumab pegol, golimumab, and post-emulsion formulations thereof.

[0145] In certain embodiments of the invention, the antibody may comprise infliximab.

[0146] In certain embodiments of the invention, the antibody may comprise a chimeric human-mouse IgG monoclonal antibody.

[0147] In one embodiment of the invention, the antibody or antigen-binding fragment thereof may comprise a light chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO:1, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:2, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:6.

[0148] In one embodiment of the invention, the antibody or antigen-binding fragment thereof may comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO:7, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8.

[0149] In one embodiment of the invention, the antibody may comprise a light chain comprising the amino acid sequence of SEQ ID NO:9 and a heavy chain comprising the amino acid sequence of SEQ ID NO:10.

[0150] In one embodiment of the invention, the concentration of the antibody or antigen-binding fragment thereof may be 10-200 mg / ml.

[0151] The present invention also provides a method for treating a disease treatable with anti-TNFα, comprising the step of subcutaneously administering to a subject a composition comprising (A) an anti-TNFα antibody or antigen-binding fragment thereof, (B) a surfactant, (C) a sugar or a derivative thereof, and (D) a buffering agent.

[0152] In certain embodiments of the present invention, the (B) surfactant may comprise a polysorbate, a poloxamer, or a mixture thereof.

[0153] In certain embodiments of the invention, the (B) surfactant may include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a mixture of two or more thereof.

[0154] In one embodiment of the present invention, the (B) surfactant may include polysorbate 80.

[0155] In one embodiment of the present invention, the concentration of the (B) surfactant may be 0.02 to 0.1% (w / v).

[0156] In some embodiments of the invention, the (C) sugar may include a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, or a mixture of two or more thereof, and the (C) sugar derivative may include a sugar alcohol, a sugar acid, or a mixture thereof.

[0157] In certain embodiments of the invention, (C) sugar or derivative thereof may comprise sorbitol, mannitol, trehalose, sucrose, or a mixture of two or more thereof.

[0158] In one embodiment of the present invention, the concentration of the (C) sugar or a derivative thereof may be 1 to 10% (w / v).

[0159] In certain embodiments of the invention, the (D) buffering agent may include acetate or histidine.

[0160] In one embodiment of the present invention, the content of the buffer (D) may be 1 to 50 mM.

[0161] In one embodiment of the invention, the composition may have a pH of 4.0 to 5.5.

[0162] In one embodiment of the invention, the composition may be free of aspartic acid, lysine, arginine, or mixtures thereof.

[0163] In some embodiments of the invention, the composition may be free of NaCl, KCl, NaF, KBr, NaBr, Na2SO4, NaSCN, K2SO4, or mixtures thereof.

[0164] In some embodiments of the invention, the composition may be free of chelating agents.

[0165] In one embodiment of the invention, the composition may be preservative-free.

[0166] In one embodiment of the invention, the composition may further comprise an aqueous carrier, an antioxidant, or a mixture of two or more thereof.

[0167] In one embodiment of the present invention, the composition may have a viscosity of 0.5 to 10.0 cp measured after storage for 1 month at a temperature of 40±2° C., or may have a viscosity of 0.5 to 5.0 cp measured after storage for 6 months at a temperature of 5±3° C.

[0168] In one embodiment of the invention, the composition may comprise: (A) an antibody or antigen-binding fragment thereof comprising a light chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 6; (B) a surfactant; (C) a sugar or a derivative thereof; and (D) a buffer comprising acetate or histidine.

[0169] In one embodiment of the present invention, the composition may contain: (A) 90 to 180 mg / ml of an antibody or antigen-binding fragment thereof comprising: a light chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 6, (B) 0.02 to 0.1% (w / v) of a surfactant, (C) 1 to 10% (w / v) of a sugar or a derivative thereof, and (D) 1 to 50 mM of a buffer containing acetate or histidine.

[0170] In one embodiment of the present invention, the composition may contain: (A) 90 to 180 mg / ml of an antibody or antigen-binding fragment thereof comprising: a light chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3; and a heavy chain variable region comprising a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 6; (B) 0.02 to 0.1% (w / v) polysorbate, (C) 1 to 10% (w / v) sorbitol, and (D) 1 to 50 mM buffer comprising an acetate.

[0171] In one embodiment of the invention, the composition may be administered subcutaneously.

[0172] In certain embodiments of the invention, the composition does not need to undergo a reconstitution step, a dilution step, or both, prior to use.

[0173] In certain embodiments of the invention, the stable composition may be loaded into a pre-filled syringe prior to use.

[0174] In one embodiment of the invention, the composition may be contained in an autoinjector prior to use.

[0175] Diseases treatable with anti-TNFα antibodies In certain embodiments of the invention, the disease treatable with an anti-TNFα antibody is selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, plaque psoriasis, arthritic psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, neonatal hemolytic disease, inflammatory bowel disease, multiple sclerosis, prevention of organ transplant rejection, non-Hodgkin's lymphoma, metastatic cancer, retinopathy of prematurity, ovarian cancer, gastric cancer, head and neck cancer, osteoporosis, paroxysmal nocturnal hemoglobinuria, invasive candidiasis, breast cancer, melanoma, chronic lymphocytic leukemia, acute myeloid leukemia, renal cell carcinoma, colorectal cancer, asthma, nasopharyngeal cancer, hemorrhagic shock, Staphylococcus aureus infection, and follicular lymphoma.

[0176] In certain embodiments of the invention, the disease treatable with an anti-TNFα antibody may be a disease treatable by intravenous administration of infliximab.

[0177] In certain embodiments of the invention, the disease treatable with an anti-TNFα antibody may be rheumatoid arthritis, ulcerative colitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, which are treatable by intravenous administration of infliximab.

[0178] In one embodiment of the invention, the subject to whom the anti-TNFα antibody is administered is a patient who has had an inadequate response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate.

[0179] In one embodiment of the invention, the subject to whom the anti-TNFα antibody is administered is a patient who has not been previously treated with methotrexate or other DMARDs.

[0180] In one embodiment of the invention, the subject to which the anti-TNFα antibody is administered is a patient who exhibits severe axial symptoms that do not respond adequately to conventional treatments and elevated serological indicators associated with inflammation.

[0181] In one embodiment of the invention, the subject to whom the anti-TNFα antibody is administered is a patient who is unresponsive to, contraindicated to, or intolerant to systemic treatments including methotrexate, cyclosporine, or cutaneous photochemotherapy (psoralen ultraviolet A therapy: PUVA).

[0182] In one embodiment of the invention, the subject to whom the anti-TNFα antibody is administered is a patient who has not responded adequately to treatment with corticosteroids, 6-mercaptopurine, azathioprine, or immunosuppressants, is intolerant to such therapy, or for whom such treatment methods are contraindicated.

[0183] In one embodiment of the invention, the subject to whom the anti-TNFα antibody is administered is a patient who has not responded to conventional treatments, including antibiotic therapy, excretion therapy, or immunosuppressive therapy.

[0184] In one embodiment of the invention, the patient after subcutaneous administration: (a) a reduction in DAS28 (Disease Activity Score in 28 joints) of at least 2.0; or (b) A decrease of at least 70 in the Crohn's Disease Activity Index (CDAI) The present invention may exhibit one or more characteristics selected from the following:

[0185] Dosage and interval In one embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 60 to 300 mg. Specifically, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, or 300 mg.

[0186] In another embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 90-180 mg. In another embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 90-300 mg. In another embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 120-240 mg.

[0187] In certain embodiments of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 80-100 mg, 110-130 mg, 170-190 mg, or 230-250 mg.

[0188] In certain embodiments of the invention, an anti-TNFα antibody or antigen-binding fragment thereof may be administered to a patient with rheumatoid arthritis at a dose of 80-190 mg, 90-180 mg, 110-130 mg, 90 mg, 120 mg, or 180 mg.

[0189] In certain embodiments of the invention, an anti-TNFα antibody or antigen-binding fragment thereof may be administered to a patient with ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, or ankylosing spondylitis at a dose of 80-250 mg, 110-250 mg, 110-130 mg, 120-240 mg, 140-160 mg, 170-190 mg, 230-250 mg, 120 mg, 150 mg, 180 mg, or 240 mg.

[0190] In one embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at a dose of 90-180 mg if the patient weighs less than 80 kg, or at a dose of 190-270 mg if the patient weighs 80 kg or more.

[0191] In certain embodiments of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at increased doses if the patient's condition does not improve or if the therapeutic response is lost. More specifically, the dose may be increased by 1.1 to 3 times, 1.1 to 2.5 times, 1.1 to 2.1 times, 1.5 to 2.1 times, 1.7 to 2.1 times, and 2 times.

[0192] For Crohn's disease, the criteria for determining loss of treatment response may be based on the patient's CDAI score increasing by 70 or more points and the patient's total CDAI score being 220 or more points. For ulcerative colitis, such criteria may be based on the patient meeting the following conditions (a) and at least one of (b) or (c): (a) Rectal bleeding subscore increased by ≥1 point from the minimum score, with the actual score being ≥1 point, and (b) A partial Mayo score increase of 2 points or more from the minimum score and an actual score of 4 points or more; or (c) The endoscopic subscore increases by 1 point or more from the minimum score, with the actual value exceeding 1 point.

[0193] In one embodiment of the invention, if the patient's condition does not improve and the dose of the anti-TNFα antibody or antigen-binding fragment thereof is increased to 240 mg, it may be preferable not to further increase the dose, since if a patient receiving a dose of 240 mg is further increased from such a dose, the high concentration of the drug may cause liver damage, etc.

[0194] In some embodiments of the present invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at increased doses at or after the 5th, 10th, 15th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 32nd, and 35th weeks. More preferably, such dose increases may be administered at or after the 30th week. If such dose increases are administered before the 30th week, there may not be enough time to confirm the medical effect of the existing dose. If such dose increases are administered after the 30th week, side effects that worsen the patient's condition may occur.

[0195] In certain embodiments of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at intervals of 1 to 8 weeks. Specifically, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at intervals of 1 week, 1.5 weeks, 2 weeks, 2.5 weeks, 3 weeks, 3.5 weeks, 4 weeks, 4.5 weeks, 5 weeks, 5.5 weeks, 6 weeks, 6.5 weeks, 7 weeks, 7.5 weeks, or 8 weeks.

[0196] In another embodiment of the invention, the anti-TNFα antibody or antigen-binding fragment thereof may be administered at intervals of 2 to 4 weeks.

[0197] In one embodiment of the invention, the minimum serum concentration (C トラフ There may be provided an administration method in which the minimum serum concentration (minimum concentration immediately before the next application) is maintained at 0.01 μg / ml or more after subcutaneous administration to a patient. More specifically, there may be provided an administration method in which the minimum serum concentration is maintained at 0.01 to 50 μg / ml, 0.01 to 45 μg / ml, 0.01 to 40 μg / ml, 0.01 to 35 μg / ml, 0.01 to 30 μg / ml, 0.01 to 25 μg / ml, 0.01 to 20 μg / ml, 0.01 to 15 μg / ml, 0.01 to 10 μg / ml, 0.01 to 6 μg / ml, 0.1 to 6 μg / ml, 5 μg / ml, or 1 μg / ml.

[0198] In one embodiment of the invention, the minimum serum concentration (C トラフ Alternatively, a method of administration may be provided in which the minimum serum concentration (C ) of the anti-TNFα antibody or antigen-binding fragment thereof is maintained at 0.01 μg / ml or more, 0.01 to 50 μg / ml, 0.01 to 40 μg / ml, 0.01 to 30 μg / ml, 1 to 40 μg / ml, or 1 μg / ml or more after subcutaneous administration to a patient with rheumatoid arthritis. Preferably, トラフ ) may be 1 μg / ml for patients with rheumatoid arthritis.

[0199] In one embodiment of the invention, the minimum serum concentration (C トラフ) is maintained at 0.01 μg / ml or more, 0.01 to 60 μg / ml, 0.01 to 50 μg / ml, 0.01 to 45 μg / ml, 5 to 50 μg / ml, or 5 μg / ml or more after subcutaneous administration to a patient having one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis.

[0200] For IBD patients, preferably, the lowest serum concentration of the anti-TNFα antibody or antigen-binding fragment thereof (C トラフ ) may be 5 μg / ml.

[0201] Premedication The step of administering the anti-TNFα antibody, or antigen-binding fragment thereof, subcutaneously may include administering the anti-TNFα antibody, or antigen-binding fragment thereof, intravenously.

[0202] In certain embodiments of the invention, the subcutaneous administration step may be preceded by at least one, and optionally two or three, intravenous administration steps of an anti-TNFα antibody or antigen-binding fragment thereof.

[0203] In one embodiment of the present invention, (a) a patient with rheumatoid arthritis may be a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously two times prior to subcutaneous administration, and (b) a patient with one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis may be a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously two or three times prior to subcutaneous administration.

[0204] In one embodiment of the invention, the patient may have received two intravenous doses of an anti-TNFα antibody or an antigen-binding fragment thereof at weeks 0 and 2 prior to subcutaneous administration, or may have received three intravenous doses of an anti-TNFα antibody or an antigen-binding fragment thereof at weeks 0, 2, and 6.

[0205] In one embodiment of the present invention, (a) a patient with rheumatoid arthritis may be a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously twice, at weeks 0 and 2, prior to subcutaneous administration, and (b) a patient with one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis may be a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously twice, at weeks 0 and 2, prior to subcutaneous administration, or a patient who has been administered an anti-TNFα antibody or an antigen-binding fragment thereof intravenously three times, at weeks 0, 2, and 6.

[0206] In some embodiments of the present invention, the method may include a step of intravenously administering an anti-TNFα antibody or an antigen-binding fragment thereof at a dose of 1 to 10 mg / kg prior to subcutaneous administration. Specifically, the method may include a step of intravenously administering an anti-TNFα antibody or an antigen-binding fragment thereof at a dose of 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg prior to subcutaneous administration.

[0207] In another embodiment of the present invention, the method may include a step of intravenously administering an anti-TNFα antibody or an antigen-binding fragment thereof at a dose of 2 to 8 mg / kg prior to the subcutaneous administration step. In another embodiment of the present invention, the method may include a step of intravenously administering an anti-TNFα antibody or an antigen-binding fragment thereof at a dose of 3 to 5 mg / kg prior to the subcutaneous administration step.

[0208] In one embodiment of the present invention, (a) a patient having rheumatoid arthritis may be a patient to whom an anti-TNFα antibody or an antigen-binding fragment thereof is administered intravenously at a dose of 3 mg / kg per administration, and (b) a patient having one or more diseases selected from the group consisting of ulcerative colitis, Crohn's disease, psoriasis vulgaris, psoriatic arthritis, and ankylosing spondylitis may be a patient to whom an anti-TNFα antibody or an antigen-binding fragment thereof is administered intravenously at a dose of 5 mg / kg per administration.

[0209] In one embodiment of the present invention, the subcutaneous administration step may be preceded by a step of intravenously administering an anti-TNFα antibody or an antigen-binding fragment thereof, and the subcutaneous administration step may be preceded by a step of administering the antibody or antigen-binding fragment thereof at an interval of 1 to 8 weeks between the last intravenous administration and the first subcutaneous administration. Specifically, the subcutaneous administration step may include a step of administering the antibody or antigen-binding fragment at an interval of 1 week, 1.5 weeks, 2 weeks, 2.5 weeks, 3 weeks, 3.5 weeks, 4 weeks, 4.5 weeks, 5 weeks, 5.5 weeks, 6 weeks, 6.5 weeks, 7 weeks, 7.5 weeks, or 8 weeks.

[0210] In another embodiment of the invention, the subcutaneous administration step may include a step of intravenously administering an anti-TNFα antibody or antigen-binding fragment thereof, and this step may include a step in which the interval between the last intravenous administration and the first subcutaneous administration is 2 to 8 weeks, 2 to 4 weeks, or 4 weeks.

[0211] In one embodiment of the present invention, a step of intravenously administering an anti-TNFα antibody or an antigen-binding fragment thereof may be included prior to the subcutaneous administration step, and the time interval between the last intravenous administration and the first subcutaneous administration may be 1 to 8 weeks. Specifically, a step of administering at intervals of 1 week, 1.5 weeks, 2 weeks, 2.5 weeks, 3 weeks, 3.5 weeks, 4 weeks, 4.5 weeks, 5 weeks, 5.5 weeks, 6 weeks, 6.5 weeks, 7 weeks, 7.5 weeks, or 8 weeks may be included.

[0212] In another embodiment of the present invention, the subcutaneous administration step may include a step of intravenously administering an anti-TNFα antibody or antigen-binding fragment thereof, and the time interval between the last intravenous administration and the first subcutaneous administration may be 2 to 4 weeks.

[0213] In another embodiment of the present invention, the time of the first subcutaneous administration is set in such a way that the level of the pre-administration concentration is close to the blood concentration at steady state during the subcutaneous administration phase, so as to minimize the possibility of ADA, which may be caused by a low concentration of infliximab in the blood. Taking the above conditions into consideration, the optimal interval between the last intravenous administration and the first subcutaneous administration was determined by a simulation performed based on the developed population PK model. As a result of the simulation, the average blood concentration was most similar to the expected level of the pre-administration concentration at steady state during the maintenance phase of subcutaneous administration 2 to 4 weeks after the last intravenous administration, more preferably 4 weeks after the last intravenous administration (i.e., the 10th week), and the change in blood concentration was also small. Therefore, by setting the time of the first subcutaneous administration at the 10th week, it is expected that the average level of the pre-administration concentration at steady state expected during the test period will be reached most quickly.

[0214] If the first subcutaneous administration is administered within 2 weeks after the last intravenous administration, the blood concentration may be higher than the expected level of the pre-administration concentration at steady state during the maintenance phase of subcutaneous administration. If the first subcutaneous administration is administered 6 weeks after the last intravenous administration, the blood concentration may be lower than the expected level of the pre-administration concentration at steady state during the maintenance phase of subcutaneous administration, and the blood concentration may reach the average level of the pre-administration concentration at steady state during the study period relatively later than when the subcutaneous administration is administered at 4 weeks (week 10). In another embodiment of the present invention, the patient may be a patient who has been intravenously administered anti-TNFα antibody or antigen-binding fragment thereof twice at weeks 0 and 2, or a patient who has been intravenously administered anti-TNFα antibody or antigen-binding fragment thereof three times at weeks 0, 2, and 6, prior to the subcutaneous administration.

[0215] Simultaneous administration Other biologics or chemotherapeutic agents may be administered together with the anti-TNFα antibody or antigen-binding fragment thereof of the invention.

[0216] Administration may occur simultaneously with, prior to, or following administration of an anti-TNFα antibody or antigen-binding fragment thereof.

[0217] In certain embodiments of the invention, the co-administered biologic may include etanercept, infliximab, adalimumab, certolizumab pegol, golimumab, or combinations thereof.

[0218] In certain embodiments of the invention, the co-administered chemotherapeutic agents may include disease-modifying antirheumatic drugs (DMARDs), steroids, or immunosuppressants.

[0219] In certain embodiments of the invention, co-administered disease-modifying antirheumatic drugs (DMARDs) may include methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or combinations thereof.

[0220] In certain embodiments of the invention, the co-administered steroid may comprise a corticosteroid, a glucocorticoid, cortisol, a mineralocorticoid, aldosterone, or a combination thereof.

[0221] In certain embodiments of the invention, co-administered immunosuppressants may include azathioprine, 6-mercaptopurine, cyclosporine A, tacrolimus, mycophenolic acid, bredinin, mTOR inhibitors, antilymphocyte antibodies, or combinations thereof.

[0222] product The invention also provides an article of manufacture comprising a composition comprising an anti-TNFα antibody, or an antigen-binding fragment thereof, and a container containing said composition in a sealed state.

[0223] The composition comprising the anti-TNFα antibody or antigen-binding fragment thereof is as described above.

[0224] In some embodiments of the invention, the container may be made of materials such as, but not limited to, glass, polymer (plastic), metal, etc. In some embodiments of the invention, the container may be, but not limited to, a bottle, a vial, a cartridge, a syringe (prefilled syringe or autoinjector), or a tube. In some embodiments of the invention, the container may be a glass or polymer vial, or a glass or polymer prefilled syringe.

[0225] The specific product forms of the above-mentioned vials, cartridges, pre-filled syringes, auto-injectors, etc., and the method of filling the stable liquid pharmaceutical formulation into the above-mentioned vials, cartridges, pre-filled syringes, auto-injectors, etc., can be easily utilized or performed by those skilled in the art to which the present invention belongs. For example, U.S. Patent No. 4,861,335 and U.S. Patent No. 6,331,174, etc. disclose specific product forms of pre-filled syringes and their filling methods. For example, U.S. Patent No. 5,085,642 and U.S. Patent No. 5,681,291, etc. disclose specific product forms of auto-injectors and their assembly methods. The above-mentioned vials, cartridges, pre-filled syringes, auto-injectors, etc. used in the present invention may be commercially available products themselves, or may be products separately manufactured in consideration of the physical properties of the composition containing an anti-TNFα antibody or an antigen-binding fragment thereof, the area to be administered, the dosage, etc.

[0226] In some embodiments of the present invention, the inside of the container may not be coated with silicone oil. If the container is coated with silicone oil, its stability may be compromised. The container may be a single dose container or a multi-dose container.

[0227] In one embodiment of the invention, the article of manufacture may further comprise instructions providing a method for using the composition comprising the anti-TNFα antibody or antigen-binding fragment thereof, a method for storing the composition, or both. The method for using the composition may include a method for treating a disease in which TNFα activity is detrimental, and may include the route of administration, dosage, and timing of administration.

[0228] In some embodiments of the invention, the product may also include other necessary means from a commercial and user standpoint, such as needles, syringes, etc. EXAMPLES

[0229] The present invention will now be described with reference to examples, however, it will be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the invention.

[0230] Example 1. Evaluation of the safety and therapeutic efficacy of subcutaneous administration of infliximab to patients with Crohn's disease (CD) or ulcerative colitis (UC) (Study 1.6) Example 1-1. Test Protocol The Study of Infliximab (CT-P13) was an open-label, randomized, multicenter, parallel-group Phase I study aimed to evaluate the pharmacokinetics, efficacy, and safety up to 54 weeks between infliximab for subcutaneous administration (hereafter referred to as infliximab SC) and infliximab for intravenous administration (hereafter referred to as infliximab IV) in patients with active CD or active UC, and the study consisted of two parts.

[0231] Part 1 aimed to identify the optimal dose of infliximab SC in patients with CD, and the optimal dose of infliximab SC equivalent to 5 mg / kg infliximab IV over the first 30 weeks was identified by the area under the concentration-time curve (AUCτ) at steady state between weeks 22 and 30. For part 1, the study period lasted up to 65 weeks, including the period from screening (up to 3 weeks) to the end-of-study visit.

[0232] Part 2 was designed to confirm that SC infliximab was not pharmacokinetically inferior to IV infliximab in patients with CD or UC, and to evaluate predose serum concentrations (C トラフThe optimal dose and dosing interval of infliximab SC equivalent to 5 mg / kg IV infliximab in part 2 was determined by an independent Data and Safety Monitoring Board (DSMB) based on pharmacokinetic, efficacy, and safety data over the first 30 weeks of part 1, as follows: *Patients weighing less than 80 kg: 120 mg infliximab SC every 2 weeks, and *Patient weight ≥80 kg: 240 mg infliximab SC every 2 weeks.

[0233] Part 1 To participate in this study, patients had to meet all of the following eligibility criteria: *Patients had active disease with a Crohn's Disease Activity Index (CDAI) score of 220 to 450 points; *Patients who were diagnosed with CD at least 3 months prior to the first administration of the study drug, and *Patients who have been treated for active CD but have not responded despite a full and adequate course of treatment with corticosteroids and / or immunosuppressants, or who have been intolerant to or have medical contraindications to such treatment.

[0234] Patients who met any of the following criteria were excluded from the study: *Patients previously treated with biologics for the treatment of CD and / or TNFα inhibitors for the treatment of other diseases. *Patients who had an allergy to any non-active components of infliximab or to any other mouse and / or human proteins, or who had a hypersensitivity to immune globulin products; *Patients with active enterovesical, enteroretroperitoneal, enterocutaneous, or enterovaginal fistulas within 6 months prior to the first administration of study drug (day 0) (enterovesical fistulas without clinically significant symptoms in the opinion of the investigator and anal fistulas without drainage problems were permitted). *Patients who had undergone 3 or more small bowel resections before the first administration of study drug (Day 0), *Patients with current or past history of chronic hepatitis C infection, human immunodeficiency virus (HIV-1 or HIV-2), or current hepatitis B infection; and *Pregnant female patients.

[0235] The study consisted of three study periods: screening, treatment period (loading and maintenance), and end of study. Screening occurred between 21 days and 1 day before the first dose of study drug to determine patient eligibility for the study. All evaluations were performed, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 or HIV-2) infection status, urine and serum pregnancy tests for women of childbearing age, colonoscopy, CRP, 12-lead electrocardiogram, and laboratory tests. Interferon-gamma release assays (IGRAs) and chest x-rays were also performed to exclude patients with active tuberculosis (TB).

[0236] On Day 0 (Week 0), patients who met all of the eligibility criteria and none of the exclusion criteria were enrolled in the study, and all participating patients received IV infliximab at Weeks 0 and 2. Patients may have been premedicated 30-60 minutes prior to the start of study drug administration, at the investigator's discretion, with medications including, but not limited to, antihistamines (at a dose equivalent to 2-4 mg chlorpheniramine), hydrocortisone, paracetamol, and / or non-sedating antihistamines (at a dose equivalent to 10 mg cetirizine).

[0237] Patients who had received two sufficient doses and had no safety concerns based on the investigator's judgment were randomly assigned to either infliximab SC or infliximab IV prior to treatment on day 42 (week 6). Randomization of treatment assignment was stratified by region (Europe or non-Europe), current use of azathioprine or 6-mercaptopurine or MTX treatment (used or unused), presence of a clinical response by CDAI-70 at week 6, and body weight at week 6 (<70 kg or ≥70 kg). A total of 45 patients with active CD were enrolled, from which 44 patients were randomly assigned in a 1:1:1:1 ratio to one of the four study cohorts at week 6 and received the study drug until week 54 (Table 1).

[0238] [Table 1]

[0239] Patients assigned to cohort 1 received seven additional doses of infliximab IV at week 6 and every 8 weeks thereafter (weeks 14, 22, 30, 38, 46, and 54). Patients assigned to cohorts 2, 3, and 4 received infliximab SC initially at week 6, then every 2 weeks until week 54. Dose escalation to 10 mg / kg was allowed in cohort 1 patients from week 30 if the patient responded initially but lost response at each visit. The initial dose assigned to all patients in cohorts 2, 3, and 4 was adjusted to the optimal dose after the optimal dose was confirmed by titration. Additional SC injections with the optimal dose were then given until week 54. Patients were injected with SC infliximab by a healthcare provider at each study site (Weeks 6, 8, 10, 14, 22, 24, 26, 28, 30, 38, 46, and 54). Patients could self-inject SC infliximab at all remaining weeks (Weeks 12, 16, 18, 20, 32, 34, 36, 40, 42, 44, 48, 50, and 52) if deemed appropriate by the investigator after appropriate training on injection technique.

[0240] Patients returned to the study site at scheduled intervals for clinical evaluation and voting. At each visit, patients were questioned about incident events (AEs) and concomitant medications and were monitored for clinical signs and symptoms of tuberculosis (TB). Primary pharmacokinetic endpoints were assessed at steady state between weeks 22 and 30, secondary pharmacokinetic endpoints were assessed during treatment through week 54, and blood samples were drawn for analysis, as well as efficacy, PD, and safety assessments, at time points specified in the schedule of events.

[0241] The end-of-study visit occurred 8 weeks after the end of the maintenance phase. However, if a patient discontinued the study, the visit occurred 8 weeks after the last dose was received. Patients who dropped out for any reason were scheduled to undergo all procedures on the day of discontinuation (or the day after discontinuation) and complete all end-of-study evaluations 8 weeks after the last dose was received.

[0242] Part 2 Part 2 was initiated based on an independent Data Safety Monitoring Board (DSMB) review of PK modeling reported data, including PK, efficacy, PD, and safety data identified over the first 30 weeks of Part 1.

[0243] To be included in the study, patients had to meet all of the following criteria:

[0244] Eligibility criteria for active Crohn's disease *Patients had active disease with a Crohn's Disease Activity Index (CDAI) score of 220 to 450 points; *Patients who were diagnosed with CD at least 3 months prior to the first administration of the study drug, and *Patients who have been treated for active CD but have not responded despite a full and adequate course of treatment with corticosteroids and / or immunosuppressants, or who have been intolerant to or have medical contraindications to such treatment. *Patients who met at least one of the following criteria: - Serum concentration of C-reactive protein (CRP) was 0.5 mg / dL or higher, fecal calprotectin concentration was ≥100 μg / g; and Simplified Endoscopic Score for Crohn's Disease (CD) (SES-CD) ≥ 6 points for ileo-colonic CD, or ≥ 4 points including ulcer score for at least one segment for ileo-colonic CD or colonic CD.

[0245] Eligibility criteria for active ulcerative colitis *Patients had active UC as defined by a total Mayo score of 6-12 points and endoscopic evidence of active ulcers as indicated by an endoscopic subscore of ≥2 at screening. *Patients had UC duration of at least 3 months prior to the first dose of study drug (Day 0). *Patients who have been treated for active UC but have failed to respond to conventional therapy, including corticosteroids alone or in combination with 6-MP or AZA, and 5-ASA-containing drugs, or who were intolerant to or had a contraindication to such therapy.

[0246] Patients who met any of the following criteria were excluded from part 2 of the study: *Patients who have previously received biologics for the treatment of CD or UC and / or TNFα inhibitors for the treatment of other diseases. *Patients who had an allergy to any non-active components of infliximab or to any other mouse and / or human proteins, or who had a hypersensitivity to immune globulin products; *Patients with active enterovesical, enteroretroperitoneal, enterocutaneous, or enterovaginal fistulas within 6 months prior to the first administration of study drug (day 0) (enterovesical fistulas without clinically significant symptoms in the opinion of the investigator and anal fistulas without drainage problems were permitted). *Patients who had undergone 3 or more small bowel resections prior to the first administration of study drug (Day 0), *UC patients who had received rectal corticosteroids or 5-aminosalicylic acid-containing medications for the treatment of UC within 2 weeks prior to screening. *Patients with UC duration ≥8 years were required to have documentation of absence of colorectal cancer or dysplasia by pan-colonoscopy performed within 1 year prior to first dose of study drug (Day 0). *Patients infected with hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 or HIV-2), and *Pregnant female patients.

[0247] Part 2 consisted of three study periods: screening, treatment, and end of study. Screening took place from 42 days before the first dose of study drug to day 0 to assess patient eligibility for the study. All tests were performed, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 or HIV-2) infection, urine and serum pregnancy tests for women of childbearing age, colonoscopy (for patients with CD), proctosigmoidoscopy (for patients with UC), CRP, 12-lead electrocardiogram, and laboratory tests. Interferon-gamma release assay (IGRA) and chest x-ray were also performed to exclude tuberculosis (TB) patients.

[0248] On day 0 (week 0), patients who met all of the eligibility criteria and none of the exclusion criteria were enrolled in the study, and infliximab IV was administered to all participating patients twice in a single dose at week 0 and week 2. Patients were eligible to receive the following premedications (e.g., antihistamines at a dose equivalent to 2-4 mg of chlorpheniramine, hydrocortisone, paracetamol, and / or non-sedating antihistamines at a dose equivalent to 10 mg of cetirizine) at 30-60 minutes prior to the start of administration of the study drug to prevent hypersensitivity to the study drug, at the discretion of the investigator.

[0249] Patients who had received two sufficient doses of study drug and no safety concerns based on the investigator's judgment were randomly assigned to receive either infliximab SC or infliximab IV prior to dosing on day 42 (week 6). This randomization of assignment to receive study drug was stratified by current use (used or unused) of azathioprine or 6-mercaptopurine or MTX treatment, presence of disease (CD or UC), presence of CD clinical response by CDAI-70 or presence of UC clinical response by partial Mayo score at week 6, and weight at week 6 (<80 kg or ≥80 kg). A total of 131 patients with active CD or active UC were randomly assigned in a 1:1 ratio to the two study treatment arms at week 6 and received study drug through week 54 (Table 2).

[0250] [Table 2]

[0251] Patients assigned to treatment arm 1 further received infliximab IV at week 6 and then every 8 weeks (weeks 14 and 22) through week 22, then such 5 mg / kg IV was changed to 120 mg or 240 mg SC at week 30, with the SC dose based on body weight at week 30. Thereafter, infliximab SC was administered at the above doses every 2 weeks through week 54. Patients assigned to treatment arm 2 received infliximab SC at the dose based on body weight at week 6, with infliximab SC at that dose every 2 weeks from week 6 through week 54. Dose escalation was permitted beginning at week 30 per investigator decision. Patients were injected with SC infliximab by a healthcare provider at every study site visit (Weeks 6, 14, 22, 24, 26, 28, 30, 38, 46, and 54). However, patients could self-inject SC infliximab during all remaining weeks if the investigator deemed it appropriate after training patients on proper injection technique.

[0252] The primary pharmacokinetic endpoint was assessed at Week 22, followed by secondary pharmacokinetic endpoints during steady state between Weeks 22 and 30, and during the treatment period through Week 54. Blood samples were collected for analysis, as well as efficacy, PD, and safety assessments, at time points specified in the event schedule.

[0253] The end-of-study visit occurred 2 weeks after the end of the maintenance phase. However, if a patient discontinued prematurely after an SC dose, such a visit occurred 2 weeks after the last dose. However, if a patient discontinued prematurely after an IV dose, such a visit occurred 8 weeks after the last dose. For patients who dropped out, all study procedures were performed on the day of dropout or the day after dropout, ensuring that all end-of-study evaluations were completed at the designated time point after the patient's last dose.

[0254] In Part 2, each type of clinical evaluation, blood draw, and study visit was conducted in the same manner as described in Part 1 at the times specified in the event schedule.

[0255] Example 1-2. Efficacy evaluation by PK-PD modeling PK-PD model development A population pharmacokinetic-pharmacodynamic (PK-PD) model for subcutaneous (SC) administration of CT-P13 was established to simulate the PK of future doses and dosing schedules as well as the efficacy of CT-P13 SC. The population PK-PD model was based on CT-P13 IV administration data from healthy volunteers (HV), patients with ankylosing spondylitis (AS), patients with rheumatoid arthritis (RA), and patients with Crohn's disease (CD), and infliximab SC administration data from patients with CD, patients with UC, patients with RA, and patients with HV (Clinicaltrials.gov identifiers NCT01220518 (Study 1.1), NCT01217086 (Study 3.1), NCT02096861 (Study 3.4), and NCT02883452 (Study 1.6)).

[0256] Using the PK-PD model developed based on the above data, the results of SC administration were simulated for patients with an indication for infliximab (RA, CD, or UC). As a result of PK-PD modeling of Part 1 of Study 1.6, Figure 1 aimed to find the optimal dose of infliximab SC injection in CD patients in Part 1. The optimal dose for Part 2 of Study 1.6 was determined based on the results of PK-PD modeling of Part 1 of Study 1.6, and the pharmacokinetic, efficacy, and safety results of Part 1 of Study 1.6. Figure 2 resulted from the PK-PD modeling of Part 2 of Study 1.6, including the results of Part 2 of Study 1.6 up to Week 30. The PK-PD modeling of Part 1 of Study 1.6 confirmed whether the optimal dose of infliximab SC for patients with inflammatory bowel disease (IBD) would achieve the target effective serum concentration (5 μg / ml). The target effective serum concentration for IBD patients was determined by a comprehensive literature search.

[0257] PK-PD modeling analyses were performed using a nonlinear mixed-effects modeling approach. The starting point for the population PK analysis of infliximab was a one-compartment infusion model using linear elimination with proportional error model, and the final model was performed with a two-compartment model showing linear elimination from a central compartment. All models were parameterized for clearance (CL) and volume (V).

[0258] Regarding the final PK models for Part 1 and Part 2, the area under the concentration-time curve (AUCτ) and minimum serum concentration (C トラフ Profiles were predicted such that each predicted value for parameters such as mean concentration (min: lowest concentration immediately before next application) was applied to each actual dose, dosing schedule, and route of administration. Additional simulations were also performed to evaluate fixed doses by body weight, dosing schedules, and routes of administration. PK-PD modeling and simulations for the subcutaneous dose in Part 1 of Study 1.6 were performed with NONMEM v7.2, and PK-PD modeling and simulations for Part 2 were performed with NONMEM v7.3.0.

[0259] As shown in Figure 1 and Tables 3 and 4 (PK-PD Modeling for Part 1 of Study 1.6), it was demonstrated that effective target effective serum concentrations (5 μg / ml) were achieved in infliximab SC administered at 120 mg, 180 mg, and 240 mg starting at week 6 compared to the control cohort (induction + 5 mg / kg IV Q8W). Additionally, it was demonstrated that each of the PK parameter values ​​increased proportionally with dose at steady state. The C was significantly higher in infliximab SC compared to the IV control cohort. トラフ is high and C max This trend was demonstrated to be due to slower absorption of the drug from the subcutaneous into the systemic circulation due to the characteristics of the SC formulation, predicting similar AUCτ between the 120 mg infliximab SC and IV subject cohorts.

[0260] [Table 3]

[0261] [Table 4]

[0262] As shown in Figure 2 (PK-PD modeling of Part 2 of Study 1.6), when 120 mg of infliximab SC was administered to CD and UC patients regardless of body weight, it was demonstrated that serum concentrations of infliximab remained consistent through steady state and above the target therapeutic concentration compared to the cohorts receiving 5 mg / kg of infliximab IV. トラフIt was also demonstrated that the Cmax and Cmax showed similar trends to those shown in the PK-PD modeling results (Figure 1) in Part 1 of Study 1.6. Based on the PK-PD modeling results in Part 2 of Study 1.6, it was predicted that administration of 120 mg SC every 2 weeks could show effective therapeutic effects in IBD patients regardless of body weight. As a result, based on the final results of PK-PD modeling, administration of 120 mg SC every 2 weeks was confirmed to be the optimal dose for IBD patients.

[0263] Example 1-3. Actual Clinical Results (Part 2 of Study 1.6) Safety assessment Example 1-3-1. Summary of adverse events Safety evaluations (secondary endpoints in Part 2) included immunogenicity, hypersensitivity monitoring (including delayed hypersensitivity monitoring), vital sign measurements (including blood pressure, heart rate, respiratory rate, and temperature), weight, interferon-gamma release assay (IGRA), chest x-ray, hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 and HIV-2) infection status, physical examination findings, 12-lead electrocardiogram, emergency events (including serious emergency events (SAEs)), emergency events of special interest (infusion-related / hypersensitivity / anaphylactic reactions (administration-related reactions), delayed hypersensitivity reactions, injection site reactions, infections, and malignancies), signs and symptoms of tuberculosis (TB), clinical laboratory analyses, pregnancy testing, self-medication and concomitant medications, and local pain using a 100-mm visual analog scale (VAS).

[0264] Cumulative safety data from this study included events reported through week 54, and an overall summary of treatment-emergent events (TEAEs) during the maintenance phase (weeks 6-54) is presented in Table 5. Overall, 363 TEAEs were reported in 87 (66.4%) patients, 38 (58.5%) patients from the 5 mg / kg IV treatment group and 49 (74.2%) patients from the 120 / 240 mg SC treatment group, respectively, showing similar rates between the two treatment groups. The majority of TEAEs were grade 1 or 2 in intensity.

[0265] Treatment-emergent serious adverse events (TESAEs) were reported in 11 (8.4%) patients: 6 (9.2%) patients from the 5 mg / kg IV treatment group and 5 (7.6%) patients from the 120 / 240 mg SC treatment group, respectively. Of all TESAEs, 3 patients (2.3%) were considered drug-related by the investigator.

[0266] TAEAs classified as administration-related reactions occurred in 2 (3.1%) patients in the 5 mg / kg IV group and 3 (4.5%) patients in the 120 / 240 mg SC group. Of the TEAEs, delayed hypersensitivity reactions occurred in only 2 (3.0%) patients in the 120 / 240 mg group.

[0267] TAEAs classified as local injection site reactions occurred in 3 (4.6%) patients in the 5 mg / kg IV group and 15 (22.7%) patients in the 120 / 240 mg SC group. A high percentage of incident events classified as injection site reactions occurred in the 120 / 240 mg SC group. A high percentage of incident events were attributable to differences in route of administration, were all grade 1 or 2 in intensity, and most patients recovered without further treatment.

[0268] TAEAs classified as infections occurred in 19 (29.2%) patients from the 5 mg / kg IV treatment group and 21 (31.8%) patients from the 120 / 240 mg SC treatment group.

[0269] TEAEs leading to discontinuation of study drug were reported in 3 (4.6%) patients in the 5 mg / kg IV treatment group and 1 (1.5%) patient in the 120 / 240 mg SC treatment group.

[0270] [Table 5]

[0271] In each collection, if a patient reported more than one event, they were counted once. Only the most serious event was counted. Each event was considered to be related to the study drug by the investigator only if the relationship was defined as "possible," "probable," or "undetermined."

[0272] Example 1-3-2. Immunogenicity evaluation As shown in Table 6 below, the percentage of ADA positive patients in the 120 / 240 mg SC treatment group was not higher than the percentage of ADA positive patients in the 5 mg / kg IV treatment group through week 30, and the percentage of patients with an ADA positive result in the 5 mg / kg IV treatment group did not increase even after switching to the 120 / 240 mg SC treatment group at week 30. The percentage of patients with an ADA positive result was generally similar between the SC and IV treatment groups through week 54, and the percentage of patients who were never identified as ADA positive after drug administration at week 0 was similar between treatment groups.

[0273] [Table 6]

[0274] *Abbreviation: ADA: anti-drug antibody, NAb: neutralizing antibody *Numerator: number of patients who were ever identified as ADA or NAb positive after study drug administration at week 0; denominator: number of patients who had ever had an immunogenicity result after study drug administration at week 0 and who had never been identified as ADA or NAb positive before study drug administration at week 0; end-of-study visits were not counted.

[0275] Example 1-3-3. Evaluation of local pain using a visual analog scale (VAS) The visual analog scale (VAS) ranged from 0 to 100 mm, with higher scores indicating more severe pain. As shown in Table 7 below, in the 120 / 240 mg SC treatment group, a somewhat higher level of VAS was observed at week 6, i.e., at the time of the first administration of infliximab SC. However, as SC administration was repeated every 2 weeks, such pain was confirmed to tend to decrease until week 38. In the case of the 5 mg / kg IV treatment group that was switched to 120 mg SC at week 30, a somewhat higher level of local site pain was observed at week 30. However, due to subsequent SC administration every 2 weeks, the local site pain decreased at week 38. Local site pain increased slightly at week 46 in both treatment groups, and then decreased at week 54.

[0276] [Table 7]

[0277] Assessment of treatment efficacy Example 1-3-4. Disease Activity Index Measured by CDAI (Patients with Crohn's Disease) As shown in Table 8 below, the median CD Activity Index (CDAI) at week 6 tended to be higher in the 120 / 240 mg SC treatment group than the 5 mg / kg IV treatment group after an IV loading regimen consisting of two doses of 5 mg / kg IV. However, CDAI scores continued to decrease in both treatment groups, such that the mean CDAI scores and the mean change from baseline in CDAI scores were similar between both treatment groups through week 30. The mean change from baseline in CDAI scores was similar between the two treatment groups through week 54, except at week 46 after the 5 mg / kg IV was switched to 120 / 240 mg SC at week 30.

[0278] [Table 8]

[0279] Example 1-3-5. Evaluation of clinical response according to CDAI-70 response criteria and CDAI-100 response criteria As shown in Table 9 below, the proportion of patients achieving a clinical response by CDAI-70 was broadly similar in the 5 mg / kg IV and 120 / 240 mg SC treatment groups through Week 30. The proportion of patients achieving a clinical response by CDAI-70 was broadly similar between the IV and SC treatment groups through Week 54, except at Week 46 after 5 mg / kg IV was switched to 120 / 240 mg SC at Week 30. Three patients in the 5 mg / kg IV treatment group had a transient increase in CDAI score and no CDAI-70 response at Week 46, but recovered their CDAI-70 response by Week 54. Response assessment by CDAI-100 response criteria showed similar results to the CDAI-70 response assessment.

[0280] [Table 9]

[0281] Example 1-3-6. Evaluation of clinical remission by CDAI As shown in Table 10 below, the proportion of patients achieving clinical remission by CDAI score was generally similar between the 5 mg / kg IV and 120 / 240 mg SC treatment groups through week 30. Clinical remission rates were generally similar between the two treatment groups through week 54 after 5 mg / kg IV was switched to 120 / 240 mg SC at week 30, with a slightly higher clinical remission rate in the 120 / 240 mg SC treatment group at week 46. This result was consistent with the clinical response results of three patients in the 5 mg / kg IV treatment group who had a transient increase in CDAI score at week 46, but these patients did not subsequently achieve clinical remission at week 46. Such patients regained clinical remission by CDAI score at week 54.

[0282] [Table 10]

[0283] Example 1-3-7. Disease Activity Index Measured by the Mayo Scoring System (Patients with Ulcerative Colitis) As shown in Table 11 below, the mean total and partial Mayo scores tended to be similar at baseline between the 5 mg / kg IV and 120 / 240 mg SC treatment groups. Additionally, there was a slightly higher improvement in total and partial Mayo scores from the 120 / 240 mg SC treatment group at week 22. However, the mean total and partial Mayo scores and change from baseline were confirmed to be similar between the two treatment groups at week 54 after the 5 mg / kg IV was switched to 120 / 240 mg SC at week 30.

[0284] [Table 11]

[0285] Example 1-3-8. Evaluation of clinical response using the Mayo scoring system As shown in Table 12 below, the percentage of patients achieving clinical response by total Mayo score was higher in the 120 / 240 mg SC treatment group than in the 5 mg / kg IV treatment group at week 22. Four patients (10.5%) in the 120 / 240 mg SC treatment group and 11 (28.2%) in the 5 mg / kg IV treatment group discontinued the study before week 22 or did not undergo endoscopy at week 22. There was a higher rate of missing data in the IV treatment group, which resulted in a relatively low clinical response rate based on total Mayo score at week 22. Clinical response rates based on total Mayo score were similar between the two treatment groups at week 54 after the 5 mg / kg IV was switched to 120 / 240 mg SC at week 30.

[0286] The proportion of patients achieving a clinical response by partial Mayo score was broadly similar between the two treatment groups through week 22, with a slightly higher response rate observed in the SC treatment group at week 30. Clinical response rates based on partial Mayo score tended to be broadly similar between the two treatment groups through week 54 after switching from 5 mg / kg IV to 120 / 240 mg SC at week 30.

[0287] [Table 12]

[0288] Example 1-3-9. Evaluation of clinical remission by Mayo score (patients with ulcerative colitis) As shown in Table 13 below, the proportion of patients achieving clinical remission by total Mayo score was higher in the 120 / 240 mg SC treatment group than in the 5 mg / kg IV treatment group at week 22. Four patients (10.5%) in the 120 / 240 mg SC treatment group and 11 (28.2%) in the 5 mg / kg IV treatment group discontinued the study before week 22 or did not undergo endoscopy at week 22. Due to a high rate of missing data in the IV treatment group, clinical remission rates based on total Mayo score were relatively low at week 22. Clinical remission rates based on total Mayo score were similar between the two treatment groups at week 54 after the 5 mg / kg IV was switched to 120 / 240 mg SC at week 30.

[0289] The proportion of patients achieving clinical remission by partial Mayo score was broadly similar between the two treatment groups through week 30, with a trend toward slightly higher clinical remission rates being observed in the 120 / 240 mg SC treatment group than in the 5 mg / kg IV treatment group through week 22. Clinical remission rates based on partial Mayo score tended to be similar between the two treatment groups through week 54 after the 5 mg / kg IV was switched to 120 / 240 mg SC at week 30.

[0290] [Table 13]

[0291] Example 1-3-10. Evaluation of efficacy by mucosal healing (patients with ulcerative colitis) As shown in Table 14 below, the proportion of patients achieving mucosal healing was higher in the 120 / 240 mg SC treatment group than in the 5 mg / kg IV treatment group at week 22. Four patients (10.5%) in the 120 / 240 mg SC treatment group and 11 (28.2%) in the 5 mg / kg IV treatment group discontinued the study before week 22 or did not undergo endoscopy at week 22. There was a high rate of missing data in the IV treatment group, which resulted in a relatively low mucosal healing rate at week 22. The proportion of patients achieving mucosal healing was similar between the two treatment groups at week 54 after the 5 mg / kg IV was switched to 120 / 240 mg SC at week 30, indicating that treatment with 120 / 240 mg SC was also effective in the 5 mg / kg IV treatment group.

[0292] [Table 14]

[0293] Pharmacokinetic evaluation Example 1-3-11. Pharmacokinetic parameters As shown in FIG. 3 and Table 15 below, the mean pre-treatment serum concentrations of infliximab were similar between the two treatment groups from weeks 0 to 6 after administration of 5 mg / kg infliximab IV at weeks 0 and 2. From the maintenance phase, the mean pre-treatment serum concentrations in the 120 / 240 mg SC treatment group increased progressively from weeks 6 to 14, with levels remaining constant from weeks 14 to 22 as a result of administration of infliximab SC every 2 weeks. The mean pre-treatment serum concentrations in the 5 mg / kg infliximab IV treatment group decreased progressively from weeks 6 to 14, with levels remaining generally constant from weeks 14 to 30 as a result of administration of infliximab IV every 8 weeks. The mean pre-treatment serum concentration levels during this period were consistently higher in the 120 / 240 mg SC treatment group compared to the 5 mg / kg IV treatment group.

[0294] Mean predose infliximab serum concentrations continued to increase after 5 mg / kg IV was switched to 120 / 240 mg SC at week 30. At week 38, such means exceeded the target effective serum concentration (5 μg / ml) and reached infliximab serum concentrations similar to those in the 120 / 240 mg SC treatment group, which remained at constant levels through week 54.

[0295] [Table 15]

[0296] *Abbreviation: AUC τ : Model predicted area under the concentration-time curve at steady state (weeks 22 to 30), C max : Model predicted maximum serum concentration, C トラフ : model predicted trough serum concentration, and CV%: coefficient of variation (%). **Patients in the 5 mg / kg IV treatment group received infliximab every 8 weeks, and patients in the 120 / 240 mg SC treatment group received infliximab every 2 weeks. Thus, PK parameters for the 5 mg / kg IV treatment group were obtained at week 22, and PK parameters for the 120 / 240 mg SC treatment group were obtained at weeks 22, 24, 26, and 28.

[0297] Example 2. Evaluation of the safety and therapeutic efficacy of subcutaneous administration of infliximab to patients with rheumatoid arthritis (RA) (Study 3.5) Example 2-1. Test Protocol The Study of Infliximab (CT-P13) was a randomized, multicenter, parallel-group Phase I / III study aimed to evaluate the pharmacokinetics, efficacy, and safety between infliximab for subcutaneous administration (hereafter referred to as infliximab SC) and infliximab for intravenous administration (hereafter referred to as infliximab IV) in combination with methotrexate (MTX) and folic acid in patients with active rheumatoid arthritis who had not shown an adequate response to treatment with MTX alone for more than 3 months. The study consisted of two parts.

[0298] Part 1 aimed to identify the optimal dose of infliximab SC equivalent to 3 mg / kg infliximab IV over the first 30 weeks, as determined by the area under the concentration-time curve (AUCτ) at steady state between weeks 22 and 30. For part 1, the study period lasted up to 65 weeks, including the period from screening (up to 3 weeks) to the end-of-study visit.

[0299] Part 2 aimed to demonstrate non-inferiority of efficacy between infliximab SC and infliximab IV. Thus, it could be demonstrated that infliximab SC was non-inferior to infliximab IV in terms of efficacy as determined by clinical response as determined by the mean change from baseline in DAS28 (Disease Activity Score in 28 joints) (C-reactive protein, CRP) in 28 joints at week 22. For part 2, the dose and interval of administration of infliximab SC was set to 120 mg every 2 weeks.

[0300] Part 1 To participate in this study, patients had to meet all of the following eligibility criteria: *Patients had active disease, defined as the presence of at least 6 of 28 swollen and tender joints, and had a serum C-reactive protein (CRP) concentration of 0.6 mg / dL or higher; and *Patients who had been treated with methotrexate at a dose of 12.5-25 mg per week (or 10-25 mg per week for Korean patients) for at least 3 months prior to administration of the study drug (week 0) and had been treated with the same dose during the last 4 weeks prior to the first dose of study drug.

[0301] Patients who met any of the following criteria were excluded from the study: *Patients who have previously received biologics for the treatment of RA and / or TNFα inhibitors for the treatment of other diseases. *Patients with known allergies to any non-active components of infliximab or to any other mouse and / or human proteins, or patients with known hypersensitivity to immune globulin products.

[0302] The study consisted of three study periods: screening, treatment, and end of study. Screening took place between 21 days and 1 day before the first dose of study drug to assess patient eligibility for the study. All evaluations were performed, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 or HIV-2) infection status, urine and serum pregnancy tests for women of childbearing age, rheumatoid factor, anti-cyclic citrullinated peptide, 12-lead electrocardiogram, and laboratory tests. Interferon-gamma release assays (IGRAs) and chest x-rays were also performed to exclude patients with TB.

[0303] All patients enrolled in the study received a single dose of infliximab IV at weeks 0 and 2, respectively. In addition, methotrexate was co-administered with folic acid to minimize or prevent AEs related to the side effects of MTX, where patients were noted to receive a maintenance dose of MTX from the beginning to the end of the study. Patients were also allowed to receive premedication 30-60 minutes prior to the start of study drug administration, including, but not limited to, antihistamines (at doses equivalent to 2-4 mg chlorpheniramine), hydrocortisone, paracetamol, and / or non-sedating antihistamines (at doses equivalent to 10 mg cetirizine), at the discretion of the investigator.

[0304] Patients who received two sufficient doses of study drug and had no safety concerns based on the investigator's judgment were randomly assigned to either the 120 mg SC treatment group or the 3 mg / kg IV treatment group prior to treatment on day 42 (week 6). Randomization was stratified by country, 2-week serum CRP concentration (<0.6 mg / dl or >0.6 mg / dl), and body weight at week 6 (<70 kg or >70 kg). A total of 50 patients with active RA were enrolled, from which 48 patients were randomly assigned in a 1:1:1:1 ratio to one of the four study cohorts at week 6 and received study drug through week 54 (Table 16).

[0305] [Table 16]

[0306] Patients assigned to cohort 1 received seven additional doses of infliximab IV at week 6 and then every 8 weeks (weeks 14, 22, 30, 38, 46, and 54). Patients assigned to cohorts 2, 3, and 4 received infliximab SC initially at week 6, then every 2 weeks until week 54. The initial dose assigned to all patients in cohorts 2, 3, and 4 was adjusted to the optimal dose after the optimal dose was confirmed by titration. Additional SC injections using the optimal dose were then given until week 54. Patients were injected with infliximab SC by their health care provider at every study site visit (weeks 6, 8, 10, 14, 22, 24, 26, 28, 30, 38, 46, and 54). Patients were able to self-inject infliximab SC during all remaining weeks (Weeks 12, 16, 18, 20, 32, 34, 36, 40, 42, 44, 48, 50, and 52) if deemed appropriate by the investigator after appropriate training in injection technique.

[0307] Patients returned to the study site at scheduled intervals for clinical evaluation and blood sampling. At each visit, patients were questioned about incident events (AEs) and concomitant medications and were monitored for clinical signs and symptoms of tuberculosis (TB). Primary pharmacokinetic endpoints were assessed at steady state between weeks 22 and 30, secondary pharmacokinetic endpoints were assessed during treatment through week 54, and blood samples were drawn for analysis, as well as efficacy, PD, and safety assessments, at time points specified in the evaluation schedule.

[0308] The end-of-study visit occurred at the end of the maintenance phase or 8 weeks after the last day of dosing if the patient dropped out. All end-of-study evaluations were completed 8 weeks after the patient's last dose.

[0309] Part 2 Part 2 was initiated based on an independent Data Safety Monitoring Board (DSMB) review of PK modeling reported data, including PK, efficacy, PD, and safety data identified over the first 30 weeks of Part 1.

[0310] Part 2 consisted of three study periods: screening, a treatment period with a double-blind period up to week 30 followed by a 24-week open-label period, and end of study. Screening took place between 42 days before the first dose of study drug and day 0 to assess patient eligibility for the study. All tests were performed, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 or HIV-2) infections, urine and serum pregnancy tests for women of childbearing age, rheumatoid factor, anti-cyclic citrullinated peptide, 12-lead electrocardiogram, and laboratory tests. Interferon-gamma release assays (IGRAs) and chest x-rays were also performed to exclude patients with TB.

[0311] All patients enrolled in the study received their first dose of infliximab IV at weeks 0 and 2, respectively. In addition, methotrexate was co-administered with folic acid to minimize or prevent AEs related to the side effects of MTX, where patients were noted to receive a maintenance dose of MTX from the beginning to the end of the study. Patients were also allowed to receive premedication 30-60 minutes prior to the start of study drug administration, including, but not limited to, antihistamines (at doses equivalent to 2-4 mg chlorpheniramine), hydrocortisone, paracetamol, and / or non-sedating antihistamines (at doses equivalent to 10 mg cetirizine), at the discretion of the investigator.

[0312] Patients who received two full doses of study drug and had no safety concerns as determined by the investigator were randomly assigned to receive either infliximab SC or placebo IV via prefilled syringe (PFS) or infliximab IV and placebo SC (PFS) prior to treatment at week 6 (day 42). Randomization was stratified by country, 2-week serum CRP concentration (≤0.6 mg / dl or >0.6 mg / dl), and weight at week 6 (≤100 kg or >100 kg). A total of 357 patients with active RA were enrolled, of which 343 patients were randomly assigned in a 1:1 ratio to the two study treatment arms and received study drug through week 54. Furthermore, blinding was maintained through week 30 using a double placebo design (Table 17).

[0313] [Table 17]

[0314] Patients assigned to arm 1 received 3 additional doses of infliximab IV at week 6 and then every 8 weeks (weeks 14 and 22) until week 22, and placebo SC at week 6 and then every 2 weeks until week 28. They were then switched to 3 mg / kg IV at week 30 and 120 mg SC (PFS). Infliximab SC (PFS) was then administered until week 54. Patients assigned to arm 2 received infliximab SC (PFS) initially at week 6, then every 2 weeks, which was continued until week 54, and placebo IV at weeks 6, 14, and 22.

[0315] Infliximab SC (placebo SC during the double-blind period) was injected by the healthcare provider to the patients at every study site visit (Weeks 6, 14, 22, 24-28 (patients visited for PK assessment), 30, 38, 46, and 54). However, patients could self-inject infliximab SC (placebo SC during the double-blind period) during all remaining weeks (Weeks 8, 10, 12, 16, 18, 20, 24-28 (patients not visited for PK assessment), 32, 34, 36, 40, 42, 44, 48, 50, and 52) if the investigator deemed it appropriate after training the patient on proper injection technique.

[0316] In certain countries, infliximab SC was self-injected every 2 weeks via an autoinjector (AI) from week 46 to week 54, then switched to self-injection of infliximab SC (PFS) from week 56 to week 64. Evaluations were performed using a pre- and post-self-injection assessment questionnaire, a self-injection assessment checklist, and a potential risk checklist so that the usefulness of infliximab SC (AI) could be evaluated.

[0317] In Part 2, each type of clinical evaluation, blood draw, and study visit was conducted in the same manner as described in Part 1 at the times specified in the evaluation schedule.

[0318] Example 2-2. Efficacy evaluation by PK-PD modeling Simulations were performed to evaluate the pharmacokinetics and efficacy (DAS28) in a cohort of RA patients receiving 120 mg of infliximab (CT-P13) subcutaneously every 2 weeks during the induction phase (weeks 0-2) without IV infliximab administration. The pharmacokinetic and efficacy (DAS28) profiles were compared to a 3 mg / kg IV cohort receiving infliximab IV at weeks 0 and 2, and a SC 120 mg experimental cohort receiving SC 120 mg every 2 weeks from week 0. Finally, the C at steady state was compared to the C at 120 mg / kg IV at week 0 and 2. トラフ and efficacy (DAS28) were compared between the two treatment cohorts.

[0319] The current PK-PD modeling for CT-P13 was based on data from a previous study of CT-P13 SC in RA patients. Specifically, data used for PK and PK-PD analytical modeling were developed based on data from seven clinical trials in different cohorts. The current PK-PD modeling was performed using a two-compartment PK model that reflects the effect of immune responses occurring in a weight- and time-dependent manner. The final PD model was an indirect response model to determine the effect of Inflixima SC on suppression of DAS28 responses. The PK-PD modeling simulations obtained from RA patients included a population PK-PD analysis using data from CT-P13 Study 3.1 and CT-P13 Study 3.5 (n=992).

[0320] Therefore, as shown in Figures 4 and 5, the results of this PK-PD modeling showed that the C トラフ The study showed that there were no significant differences between the two treatment cohorts in terms of efficacy (DAS28) and outcome (DAS28). In the cohort receiving 120 mg infliximab SC every 2 weeks starting from week 0, the median C トラフwas higher than the target effective serum concentration, i.e., 1 μg / ml. Efficacy (DAS28) was similar between the two dosing regimens, demonstrating that the modeling identified that the target serum concentration was achieved, and also confirming that 120 mg infliximab SC every 2 weeks is the optimal dose for RA patients.

[0321] Example 2-3. Actual Clinical Results (Part 2 of Study 3.5) Safety assessment Example 2-3-1. Summary of adverse events Safety evaluations included secondary endpoints such as immunogenicity, hypersensitivity monitoring (including delayed hypersensitivity monitoring), vital sign measurements (including blood pressure, heart rate, respiratory rate, and temperature), body weight, interferon gamma release assay, chest x-ray, hepatitis B, hepatitis C, and human immunodeficiency virus (HIV-1 and HIV-2) infection status, physical examination findings, 12-lead electrocardiogram, emergency events (including serious emergency events), emergency events of special interest (infusion-related / hypersensitivity / anaphylactic reactions (administration-related reactions), delayed hypersensitivity reactions, injection site reactions, infections, and malignancies), signs and symptoms of tuberculosis, clinical laboratory analyses, pregnancy testing, self-administered and concomitant medications, and local pain using a 100-mm visual analog scale (VAS).

[0322] Cumulative safety data included treatment-emergent events (TEAEs) (and serious emergency events) regardless of study drug-relatedness through the end-of-study visit, and an overall summary of TEAEs during the maintenance phase (weeks 6-64) is presented in Table 18. Overall, 622 TEAEs occurred in 209 (60.9%) patients, i.e., 117 (66.9%) patients from the 3 mg / kg IV treatment group and 92 (54.8%) patients from the 120 mg SC treatment group, respectively, showing similar proportions between the two treatment groups. Furthermore, the majority of TEAEs were of grade 1 or 2 intensity. Of all the emergency events, TEAEs reported in a total of 145 patients (42.3%) were considered to be study drug-related by the investigator.

[0323] Treatment-emergent serious adverse events (TESAEs) were reported in 19 (5.5%) patients, 13 (7.4%) patients in the 3 mg / kg IV group and 6 (3.6%) patients in the 120 mg SC group, respectively. The majority of TESAEs were grade 3 or less in intensity, with TESAEs considered by the investigator to be related to study drug reported in 4 (2.3%) patients in the 3 mg / kg IV group and 3 (1.8%) patients in the 120 mg SC group. Additionally, permanent study drug discontinuation as determined by the investigator was reported in a total of 20 (5.8%) patients (14 (8.0%) patients in the 3 mg / kg IV group; 6 (3.6%) patients in the 120 mg SC group) of all TESAEs.

[0324] Among the TAEA classified as administration-related reactions, including infusion-related reactions (IRR) and systemic injection reactions (SIR), hypersensitivity or anaphylactic reactions were reported in a total of 15 (4.4%) patients, i.e., 10 (5.7%) patients from the 3 mg / kg IV treatment group and 5 (3.0%) patients from the 120 mg SC treatment group. Among the patients reported as IRR (10 from 3 mg / kg IV; 2 from 120 mg SC), a total of 6 patients had positive results for anti-drug antibodies (ADA), of which 5 patients reported positive results for NAbs. Of the 15 patients reported as administration-related reactions, 6 patients had received prior medication.

[0325] TEAEs classified as infections were reported in 60 (34.3%) patients from the 3 mg / kg IV treatment group and 49 (29.2%) patients from the 120 mg SC treatment group.

[0326] [Table 18]

[0327] *At each level, if a patient reported two or more events, they were counted once. Only the most serious event was counted. Each event was considered related only if the relationship was defined as "possible," "probable," or "undetermined."

[0328] Example 2-3-2. Immunogenicity evaluation As shown in Table 19 below, the percentage of patients with a positive ADA result in the 120 mg SC treatment group was similar to or slightly lower than the percentage of patients with a positive ADA result in the 3 mg / kg IV treatment group.

[0329] [Table 19]

[0330] *Abbreviation: *ADA: Anti-drug antibody; NAb: Neutralizing antibody **Numerator: Patients who were never identified as ADA and NAb positive until the end-of-study visit after the first dose were used for the count (however, ADA or NAb results prior to dosing (baseline visit) were not considered for the count).

[0331] Example 2-3-3. Evaluation of local pain using a visual analog scale (VAS) The visual analog scale (VAS) ranged from 0 to 100 mm, with higher scores indicating more severe pain. As shown in Table 20 below, a somewhat higher level of VAS was observed at the first dose of infliximab SC (week 6) in the 120 mg SC treatment group. However, as SC administration was repeated, the local pain gradually decreased, and similar levels of pain were reported in both treatment groups. Local pain in the 120 mg SC treatment group decreased until week 46. All patients in the 3 mg / kg IV treatment group were switched to infliximab SC at week 30, and higher levels of local site pain than in the 120 mg SC treatment group were observed from week 30, but there was a trend for the local pain level to gradually decrease until week 46.

[0332] [Table 20]

[0333] Assessment of treatment efficacy Example 2-3-4. Disease Activity Index Measured by DAS28 The primary efficacy outcome was clinical response as measured by change from baseline in DAS28 (C-reactive protein; CRP) at Week 22, as assessed using ANCOVA (analysis of covariance), which demonstrated that 120 mg SC was non-inferior to 3 mg / kg IV. Least squares regression of disease activity index as measured by DAS28 is summarized in Table 21, and actual values ​​and change from baseline are summarized in Table 22.

[0334] [Table 21]

[0335] [Table 22]

[0336] Example 2-3-5. ACR20, 50, 70 response evaluation The percentage of patients with clinical response according to ACR20 (American College of Rheumatology) response assessment was similar between the 3 mg / kg IV and 120 mg SC treatment groups through week 22 (Table 23). However, slightly higher response rates were observed in the 120 mg SC treatment group at week 30 (133 (76.4%) patients from the 3 mg / kg IV treatment group; 142 (86.1%) patients from the 120 mg SC treatment group). Response rates were slightly higher after the 3 mg / kg IV treatment group was switched to 120 mg at week 30, but an overall trend toward a gradual increase in response rates was observed. Similar trends were observed for ACR50 and ACR70.

[0337] [Table 23]

[0338] Example 2-3-6. EULAR reaction evaluation The proportion of patients with a good or moderate-to-severe response on the European League Against Rheumatism (EULAR) response assessment, classified according to DAS28(CRP), was similar between treatment groups through week 22 but was slightly higher in the 120 mg SC treatment group at week 30. However, EULAR response rates at week 54 were similar between treatment groups after the 3 mg / kg IV treatment group was switched to 120 mg at week 30 (Table 24).

[0339] [Table 24]

[0340] Pharmacokinetic evaluation Example 2-3-7. Pharmacokinetic parameters After infliximab IV at 3 mg / kg at weeks 0 and 2, mean pre-dose serum concentrations of infliximab were similar between treatment groups through week 6. From the maintenance phase, mean pre-dose serum concentrations of infliximab gradually increased in the 120 mg SC every 2 weeks treatment group through week 14, then remained constant from week 14 to week 54. Mean pre-dose serum concentrations of infliximab gradually decreased in the 3 mg / kg IV treatment group at 8-week intervals through week 14, then remained constant from week 14 to week 30. Pharmacokinetic profiles showed differences through week 30 due to differences in formulation and dosing interval between 3 mg / kg infliximab IV and 120 mg infliximab SC. However, mean serum concentrations increased (from weeks 30 to 46) after the 3 mg / kg IV treatment group was switched to 120 mg at week 30, and concentrations at week 54 were similar between the treatment groups (Figure 6).

[0341] Pharmacokinetic evaluation parameters (AUCτ, C max , and C トラフ) was predicted. C max and C トラフ showed a flatter profile in the 120 mg SC group than in the 3 mg / kg IV group from weeks 22 to 30, and the predicted C トラフ was higher than the target effective serum concentration, i.e., 1 μg / ml (Table 25).

[0342] [Table 25]

[0343] *Abbreviation: AUC τ : Model predicted area under the concentration-time curve at steady state (weeks 22 to 30), C max : Model predicted maximum serum concentration, C トラフ : model predicted trough serum concentration, and CV%: coefficient of variation (%). **Patients from the 3 mg / kg IV treatment group received infliximab every 8 weeks, and patients from the 120 mg SC treatment group received infliximab every 2 weeks. Thus, PK parameters for the 3 mg / kg IV treatment group were obtained at week 22, and PK parameters for the 120 mg SC treatment group were obtained at weeks 22, 24, 26, and 28. Thus, pharmacokinetic parameters for the 3 mg / kg IV treatment group were evaluated at week 22, and pharmacokinetic parameters for the 120 mg SC treatment group were evaluated at weeks 22, 24, 26, and 28.

[0344] Example 3. Evaluation of the efficacy and safety of subcutaneous injections of infliximab as maintenance therapy in patients with Crohn's disease (CD) (Study 3.8) Example 3-1. Test Protocol This study was a randomized, placebo-controlled, double-blind, multicenter, parallel-group, phase III study aimed to evaluate the efficacy, PK, PD, usefulness, and safety of infliximab (CT-P13) SC.

[0345] The study consisted of three study periods: screening, treatment periods (induction, maintenance, and extension), and an end-of-study visit.

[0346] Screening period: Screening occurred between days 42 and 0 (maximum 6 weeks) prior to the first dose of IV infliximab administered during the induction phase.

[0347] To participate in this study, patients had to meet all of the following eligibility criteria: *Patients were male or female, aged 18 to 75 years. *Patients had moderate to severe active CD with a CDAI score of 220-450 points. *Patients who had ileo-colonic CD with a simplified endoscopic activity score for CD of ≥6 points, or patients who had ileo-colonic CD with a simplified endoscopic activity score of ≥4 points and ulcer score for at least one segment, *Patients with CD diagnosed by radiography, biopsy, or endoscopy at least 3 months prior to the first day of administration of the study drug. *Patients who had previously received adequate treatment for active CD with corticosteroids and / or immunosuppressants but had failed to respond, or who were intolerant or had medical contraindications to such treatment.

[0348] Patients who met any of the following criteria were excluded from the study: *Patients who had previously received two or more biologics, two or more Janus kinase (JAK) inhibitors, or two or more of both a biologic and a JAK inhibitor. *Patients who used TNFα inhibitors or biologics within 5 half-lives based on the first dose of study drug (day 0) *Patients who have not previously responded to or have not tolerated TNFα inhibitors used to treat CD, and *Patients who previously used infliximab for treatment of CD or other diseases.

[0349] Treatment period *Open-label run-in phase (administered at weeks 0, 2, and 6) *Double-blind maintenance phase (administered from week 10 to week 54) *Open-label extension phase (administered from week 56 to week 102)

[0350] In the open-label induction phase, only patients who met all of the inclusion criteria and did not meet any of the exclusion criteria based on Day 0 (Week 0) were enrolled in the study. All enrolled patients visited Weeks 0, 2, and 6 for induction treatment and received infliximab IV (5 mg / kg) over 2 hours. Patients who received three doses of sufficient infliximab by IV infusion, were classified as responders at Week 10 by CDAI-100, and had no safety concerns as determined by the investigator, were randomly assigned to receive infliximab SC or placebo SC before treatment on Day 70 (Week 10).

[0351] This random allocation of study drug treatment was stratified according to the following criteria: * Prior use (with or without) of biologics and / or JAK inhibitors; * Use of oral corticosteroid treatment (used or not) at week 0, and *Achievement of clinical remission at week 10 (achieved or not achieved remission by CDAI score).

[0352] The double-blind maintenance phase consisted of additional doses of infliximab SC or placebo SC, with the last dose administered at week 54. *Study Arm 1) 120 mg infliximab SC every 2 weeks: Patients received 120 mg infliximab SC every 2 weeks from weeks 10 to 54 based on PFS. *Arm 2) Placebo SC every 2 weeks: Placebo SC was administered every 2 weeks from Week 10 to Week 54 based on PFS.

[0353] In the open-label extension phase, patients who completed the maintenance phase by week 54 and who, in the opinion of the investigator, would benefit from continued treatment received 120 mg of infliximab SC by PFS or AI. Patients who received 240 mg of infliximab SC in the maintenance phase received the same dose of infliximab SC in the extension phase. The extension phase continued through week 102.

[0354] If a patient initially responded to the drug regardless of the assigned group but subsequently lost response, the patient was permitted to receive an adjusted dose of 240 mg infliximab SC (double injections (2x) of 120 mg infliximab SC) every 2 weeks starting at week 22. Loss of response was defined as a total CDAI score of ≥220 and an increase in the CDAI of ≥200 points from the week 10 CDAI score.

[0355] Patients may be premedicated 30-60 minutes prior to administration of infliximab IV, and may be administered antihistamines (at a dose equivalent to 2-4 mg chlorpheniramine), hydrocortisone, paracetamol, and / or non-sedating antihistamines (at a dose equivalent to 10 mg cetirizine) during the treatment phase at the investigator's discretion. Patients may also be premedicated during administration of infliximab SC at the investigator's discretion.

[0356] End of study visit The final study termination visit occurred 4 weeks after the last dose. For patients who discontinued study treatment early, before being switched to SC infliximab or SC placebo at week 10, the study termination visit occurred 8 weeks after the last IV infliximab was administered.

[0357] Example 3-2. PK data and PK-PD modeling for CD patients The dose and interval of administration of CT-P13 used in Study 3.8 was determined based on the results of Part 1 of Study 1.6 for CT-P13 and the results of the population PK analysis. The PK-PD model was based on CT-P13 IV administration data for healthy volunteers, patients with AS, patients with RA, and patients with CD, and infliximab SC administration data for patients with CD, patients with RA, and healthy volunteers (Clinicaltrials.gov identifiers NCT01220518 (Study 1.1), NCT01217086 (Study 3.1), NCT02096861 (Study 3.4), NCT03147248 (Study 3.5), and NCT02883452 (Study 1.6).

[0358] Using the PK-PD model developed based on the above data, we simulated the outcomes of SC administration for patients with an indication for infliximab (RA, UC, CD, plaque psoriasis, psoriatic arthritis, or AS).

[0359] For population PK and PK-PD modeling for CD patients, the total CDAI score was included in the analysis as well as safety for the indications (CD, RA, and AS). The final PK model was performed with a two-compartment model with a depot compartment showing linear elimination from the central compartment where infliximab infusion occurs and a first-order absorption rate towards the central compartment. A covariance relationship between disease duration and baseline CDAI score was applied to this model. Validation of the PK-PD modeling was performed by visual posterior predictive performance assessment (VPC).

[0360] Figure 7 is a graph comparing the observed CDAI scores (shown as circles) and the model-predicted CDAI scores (solid black line) as a result of the VPC obtained from the final PK-PD model. Although data from Study 1.6 Part 1 for CT-P13 was limited, the VPC confirmed a good degree of agreement between the observed and simulated data, as shown in the results in Figure 7.

[0361] Example 3-3. Exposure-response evaluation of efficacy from CD patients Simulations of mean serum concentrations over time were performed for various doses of infliximab SC (120 mg, 150 mg, and 240 mg), as shown in Figure 8. All simulated doses of infliximab SC were significantly higher than the C of the IV reference drug from weeks 10 to 30. トラフ A sustained higher level of C トラフ The results were consistent with those of part 1 of Study 1.6 for infliximab.

[0362] Furthermore, Figure 9 confirms that no particular differences are expected between the predicted CDAI scores after administration of infliximab SC at different doses.

[0363] Based on the simulation results, all three SC doses of 120 mg, 150 mg, and 240 mg consistently produced high levels of C from weeks 10 to 30. トラフ maintains the dose, and therefore all doses are determined as optimal doses. Of these doses, it has been demonstrated that 120 mg is the most efficient dose to achieve the desired level of efficacy at the last drug exposure. Furthermore, in part 1 of Study 1.6 on infliximab, no safety issues were observed from the 120 mg infliximab SC cohort, and the number of patients with positive results for anti-drug antibodies (ADA) or neutralizing antibodies (NAb) was the smallest in the 120 mg infliximab SC cohort. Therefore, the applicants propose to administer 120 mg infliximab every 2 weeks from week 10 through the follow-up study of Study 3.8 on infliximab.

[0364] Example 3-4. Basis for time point of first subcutaneous administration (week 10) In the proposed dosing regimen, the dosing method during the IV induction phase was the same as that conventionally applied for infliximab. IV administration was performed at a dose of 5 mg / kg over approximately 2 hours at weeks 0, 2, and 6. SC administration was then started at week 10, i.e., 4 weeks after the administration of the last IV induction dose at week 6. At the start of the first SC administration, C トラフ Levels were maintained near steady-state plasma concentrations throughout the SC administration regimen.

[0365] Based on the PK modeling data, a simulation was performed to find the optimal time point for the first SC administration. According to the simulated plasma concentration (±SD) profile of infliximab, the plasma concentration at week 10, i.e., 4 weeks after the last IV induction at week 6, was set to be close to the mean plasma concentration after the three IV induction doses at weeks 0, 2, and 6. The C at steady state was 0.01–0.05 at week 10 and subsequently at 2-week intervals when SC was administered. トラフ was predicted during the maintenance phase of infliximab SC, and it was confirmed that the fluctuation of PK concentrations was small (Figure 8). Therefore, the predicted mean C トラフ was well maintained throughout the study, demonstrating that steady state was reached rapidly when SC dosing was initiated at week 10.

[0366] As a result, the PK-PD modeling and simulation results confirmed that all dosing regimens of CT-P13 SC achieved sufficient efficacy from CD patients without unexpected safety signals. Simulation was successfully used to identify the optimal dosing regimen of infliximab SC that can be administered to SC patients in the future.

[0367] From a simulation study of CD patients following up, 120 mg of infliximab SC every 2 weeks seems to be the most appropriate. Therefore, we propose an IV induction dose of 5 mg / kg at weeks 0, 2, and 6, followed by a maintenance dose of 120 mg of infliximab SC every 2 weeks after starting SC treatment at week 10.

[0368] Example 4. Evaluation of the Efficacy and Safety of Subcutaneous Infliximab as Maintenance Therapy in Patients with Ulcerative Colitis (UC) (Study 3.7) Example 4-1. Test Protocol This study was a randomized, placebo-controlled, double-blind, multicenter, parallel-group, phase III trial aimed to evaluate the efficacy, PK, PD, and safety of infliximab SC.

[0369] The study consisted of three study periods: screening, treatment periods (induction, maintenance, and extension), and an end-of-study visit.

[0370] Screening period: Screening occurred between 42 days prior to and day 0 (maximum 6 weeks) prior to the first dose of IV infliximab administered during the induction phase.

[0371] To participate in this study, patients had to meet all of the following eligibility criteria: *Patients were male or female, aged 18 to 75 years. *Patients had moderate to severe active UC with a modified Mayo score of 5 to 9 points. *Patients diagnosed with UC by endoscopy or X-ray and biopsy, and *Patients who had been treated for active UC but had not responded to common treatments such as corticosteroids and / or 6-mercaptopurine, azathioprine, or who were intolerant or had medical contraindications to such treatment.

[0372] Patients who met any of the following criteria were excluded from the study: *Patients who had previously used two or more biologics, two or more Janus kinase (JAK) inhibitors, or two or more of both a biologic and a JAK inhibitor. * Patients in whom a TNFα inhibitor or biologic can be detected in serum or within 5 half-lives of the first dose of investigational drug (Day 0); *Patients who have received a TNFα inhibitor for the treatment of UC but have not responded to or have not tolerated such therapy, or *Patients who have previously used infliximab for treatment of UC or other diseases.

[0373] Treatment period *Open-label run-in phase (administered at weeks 0, 2, and 6) *Double-blind maintenance phase (administered from week 10 to week 54) *Open-label extension phase (administered from week 56 to week 102)

[0374] In the open-label induction phase, only patients who met all of the inclusion criteria and did not meet any of the exclusion criteria based on Day 0 (Week 0) were enrolled in the study. All enrolled patients visited Weeks 0, 2, and 6 for induction treatment and received infliximab IV (5 mg / kg) over 2 hours. Patients who received three doses of sufficient infliximab by IV infusion, were classified as responders at Week 10 by Mayo score, and had no safety concerns as determined by the investigator, were randomly assigned to receive infliximab SC or placebo SC prior to treatment on Day 70 (Week 10).

[0375] This random allocation of study drug treatment was stratified according to the following criteria: * Prior use (with or without) of biologics and / or JAK inhibitors; * Use of oral corticosteroid treatment (used or not) at week 0, and *Achievement of clinical remission at 10 weeks (achieved or not achieved remission by modified Mayo score).

[0376] The double-blind maintenance phase consisted of additional doses of infliximab SC or placebo SC, with the last dose administered before week 54. *Arm 1. Infliximab SC 120 mg every 2 weeks: PFS received infliximab SC 120 mg every 2 weeks from weeks 10 to 54. *Arm 2. Placebo SC every 2 weeks: Placebo SC was administered every 2 weeks from Week 10 to Week 54 by PFS.

[0377] In the open-label extension phase, patients who completed the maintenance phase by week 54 and who, in the opinion of the investigator, would benefit from continued treatment were extended into the open-label extension phase. Treatment in the extension phase began at week 56 and continued through week 102. Patients who received 120 mg infliximab SC or placebo SC continued to receive 120 mg infliximab SC at week 54. Patients who received 240 mg infliximab SC at week 54 continued to receive the same dose of infliximab SC in the extension phase.

[0378] If a patient initially responded to the drug but subsequently lost response regardless of group assignment, they were permitted to receive an up-titration of 240 mg infliximab SC (double injections of 120 mg infliximab SC) every 2 weeks starting at week 22. Loss of response was defined as any one of the following: an increase of ≥2 points or ≥30% in the modified Mayo score compared with week 10, a total score of ≥5 points, and an endoscopic score of ≥2 points.

[0379] Patients may be premedicated 30-60 minutes prior to the start of infliximab IV administration and may be administered antihistamines (at a dose equivalent to 2-4 mg chlorpheniramine), hydrocortisone, paracetamol, and / or non-sedating antihistamines (at a dose equivalent to 10 mg cetirizine) during the treatment phase at the investigator's discretion. Patients may also be premedicated during administration of subcutaneous injections at the investigator's discretion.

[0380] End of study visit The final study exit visit occurred 4 weeks after the last dose. For patients who discontinued study treatment earlier, before being switched to SC infliximab or SC placebo, the study exit visit occurred 8 weeks after the last IV infliximab was administered.

[0381] Example 4-2. PK data and PK-PD modeling for CD patients The dose and interval of administration of CT-P13 used in Study 3.7 was determined based on the results of Part 1 of Study 1.6 for CT-P13. The PK-PD model was based on CT-P13 IV administration data for healthy volunteers, patients with AS, patients with RA, and patients with CD, and infliximab SC administration data for patients with CD, patients with RA, and healthy volunteers (Clinicaltrials.gov identifiers NCT01220518 (Study 1.1), NCT01217086 (Study 3.1), and NCT02096861 (Study 3.4)).

[0382] The PK-PD model developed based on the above data may be used to simulate the outcomes of SC administration for patients with an indication for infliximab (RA, UC, CD, plaque psoriasis, psoriatic arthritis, or AS).

[0383] For population PK and PK-PD modeling for UC patients, Mayo score was included in the analysis as well as safety for indications (CD, RA, and AS). The final PK model was performed with a two-compartment model with a depot compartment showing linear elimination from the central compartment where infliximab infusion occurs and a first-order absorption rate towards the central compartment. In the final PD model, the covariance relationship between disease duration and baseline Mayo score was applied to the model.

[0384] Example 4-3. Exposure-response evaluation of efficacy from UC patient data The mean serum concentrations over time were simulated for various doses (120 mg and 240 mg) of CY-P13 SC, as shown in Figure 10. All simulated doses of infliximab SC produced consistently higher levels of C than the IV reference drug from weeks 10 to 30. トラフ The results were consistent with those of parts 1 and 2 of Study 1.6 for infliximab.

[0385] Furthermore, from FIG. 11 it could be seen that there was no particular difference between the predicted Mayo scores after administration of infliximab SC at different doses, confirming that 120 mg and 240 mg all had similar effects.

[0386] Based on the simulation results, both the 120 mg and 240 mg SC doses produced sustained high levels of C, including at steady state from weeks 10 to 54. トラフ Since the doses were maintained, both doses are determined as optimal doses. Of these doses, 120 mg was identified as the most efficient dose to achieve the desired level of efficacy at the last drug exposure. Furthermore, in part 1 of study 1.6 on infliximab, no safety issues were observed from the 120 mg infliximab SC cohort, and the number of patients with positive results for anti-drug antibodies (ADA) or neutralizing antibodies (NAb) was the smallest in the 120 mg infliximab SC cohort. Therefore, for study 3.7 of follow-up CT-P13, we propose to administer 120 mg infliximab every 2 weeks from week 10.

Claims

1. A pharmaceutical composition for treating a TNFα-related disease, comprising infliximab, Infliximab is administered subcutaneously at a dose of 120 mg and at two-week intervals to patients with TNFα-related disorders; the TNFα-related disease is rheumatoid arthritis; the patient has received infliximab intravenously at a dose of 3 mg / kg per administration prior to the subcutaneous administration; The first subcutaneous dose is administered 4 weeks after the last intravenous dose. The pharmaceutical composition.

2. A pharmaceutical composition for treating a TNFα-related disease, comprising infliximab, Infliximab is administered subcutaneously to patients with TNFα-related disorders at doses of 120 mg or 240 mg and at two-week intervals; the TNFα-related disease is ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis vulgaris, or psoriatic arthritis; the patient has received infliximab intravenously at a dose of 5 mg / kg per administration prior to the subcutaneous administration; The first subcutaneous dose is administered 4 weeks after the last intravenous dose. The pharmaceutical composition.

3. The pharmaceutical composition described in claim 1 or claim 2, wherein infliximab is administered in combination with one or more selected from the group consisting of disease-modifying antirheumatic drugs (DMARDs), steroids, and immunosuppressants.

4. the disease-modifying antirheumatic drug (DMARD) is selected from the group consisting of methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine; the steroid is selected from the group consisting of corticosteroids, glucocorticoids, cortisol, mineralocorticoids, and aldosterone; the immunosuppressant is selected from the group consisting of azathioprine, 6-mercaptopurine, cyclosporine A, tacrolimus, mycophenolic acid, bredinin, mTOR inhibitors, and anti-lymphocyte antibodies; The pharmaceutical composition according to claim 3.

5. The pharmaceutical composition of claim 1, wherein the patient has received two or three intravenous doses of infliximab prior to subcutaneous administration.

6. The patient has received two doses of intravenous infliximab prior to subcutaneous administration. The pharmaceutical composition according to claim 5.

7. The pharmaceutical composition described in claim 2, wherein the patient has received two or three intravenous doses of infliximab prior to subcutaneous administration.

8. The pharmaceutical composition described in claim 7, wherein the patient has received three intravenous doses of infliximab prior to subcutaneous administration.

9. The pharmaceutical composition according to claim 1 or claim 2, wherein the patient is a patient who has received infliximab intravenously twice at weeks 0 and 2, or a patient who has received infliximab intravenously three times at weeks 0, 2, and 6, prior to subcutaneous administration.

10. The minimum serum concentration of infliximab (C トラフ 2. The pharmaceutical composition of claim 1, wherein the concentration of 0.01 μg / ml or more is maintained at or above 0.01 μg / ml following subcutaneous administration to said patient.

11. The minimum serum concentration of infliximab (C トラフ ) is maintained at 1 μg / ml or more following subcutaneous administration to said patient; The pharmaceutical composition according to claim 10.

12. The pharmaceutical composition of claim 2, wherein the minimum serum concentration (C trough) of infliximab is maintained at or above 0.01 μg / ml following subcutaneous administration to the patient.

13. The pharmaceutical composition of claim 12, wherein the minimum serum concentration (C trough) of infliximab is maintained at or above 5 μg / ml following subcutaneous administration to the patient.

14. 2. The pharmaceutical composition of claim 1, wherein the patient after subcutaneous administration is characterized by a reduction in DAS28 (Disease Activity Score in 28 joints) of at least 2.

0.

15. The pharmaceutical composition of claim 2, wherein the patient after subcutaneous administration is characterized by a reduction in CDAI (Crohn's Disease Activity Index) of at least 70.

16. The patient prior to subcutaneous administration: (a) inadequate response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate; (b) not previously treated with methotrexate or other DMARDs; (c) exhibiting severe axial symptoms and elevated serologic indicators associated with inflammation that do not respond adequately to conventional treatment; or (d) Unresponsive to, contraindicated to, or intolerant to methotrexate having one or more of the following characteristics: The pharmaceutical composition of claim 1.

17. The patient prior to subcutaneous administration: (a) inadequate response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate; (b) not previously treated with methotrexate or other DMARDs; (c) exhibiting severe axial symptoms and elevated serologic indicators associated with inflammation that do not respond adequately to conventional treatment; or (d) unresponsiveness to, contraindication to, or intolerance to systemic treatment, including methotrexate, cyclosporine A, or cutaneous photochemotherapy (psoralen ultraviolet A therapy: PUVA); having one or more of the following characteristics: The pharmaceutical composition according to claim 2.

18. The patient prior to subcutaneous administration: (a) inadequate response to, intolerance to, or contraindication to treatment with corticosteroids, 6-mercaptopurine, azathioprine, or immunosuppressants; or (b) failure to respond to common treatments, including antibiotic therapy, excretion therapy, or immunosuppressive therapy; having one or more of the following characteristics: The pharmaceutical composition according to claim 1 or claim 2.

19. The pharmaceutical composition according to claim 1 or claim 2, wherein the pharmaceutical composition containing infliximab comprises: (A) 90 to 180 mg / ml infliximab; (B) 0.02 to 0.1% (w / v) polysorbate; (C) 1 to 10% (w / v) sorbitol; and (D) 1 to 50 mM buffer containing acetate.

20. The pharmaceutical composition of claim 1 or claim 2, wherein the pharmaceutical composition containing infliximab is loaded into a prefilled syringe or an autoinjector prior to administration to the patient.

21. (a) the pharmaceutical composition of claim 1, and (b) instructions to administer infliximab subcutaneously at a dose of 120 mg and at two-week intervals to treat a patient with rheumatoid arthritis; A kit comprising: the patient has received infliximab intravenously at a dose of 3 mg / kg per administration prior to the subcutaneous administration; The pharmaceutical composition is administered to the patient such that the first subcutaneous administration occurs 4 weeks after the last intravenous administration. The kit. (a) a pharmaceutical composition according to claim 2, and (b) instructions to administer infliximab subcutaneously at doses of 120 mg or 240 mg at two-week intervals to treat a patient with ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, or psoriatic arthritis; A kit comprising: the patient has received infliximab intravenously at a dose of 5 mg / kg per administration prior to the subcutaneous administration; The pharmaceutical composition is administered to the patient such that the first subcutaneous administration occurs 4 weeks after the last intravenous administration. The kit.

23. Use of infliximab in the preparation of a pharmaceutical composition according to claim 1 to be administered to a patient for treating a TNFα-related disease, comprising: the TNFα-related disease is rheumatoid arthritis; Infliximab was administered subcutaneously at a dose of 120 mg and at two-week intervals; the patient has received infliximab intravenously at a dose of 3 mg / kg per administration prior to the subcutaneous administration; The pharmaceutical composition is administered to the patient such that the first subcutaneous administration occurs 4 weeks after the last intravenous administration. The above uses.

24. Use of infliximab in the preparation of a pharmaceutical composition according to claim 2 to be administered to a patient for treating a TNFα-related disease, comprising: the TNFα-related disease is ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis vulgaris, or psoriatic arthritis; Infliximab is administered subcutaneously at a dose of 120 mg or 240 mg and at two-week intervals; the patient has received infliximab intravenously at a dose of 5 mg / kg per administration prior to the subcutaneous administration; The pharmaceutical composition is administered to the patient such that the first subcutaneous administration occurs 4 weeks after the last intravenous administration. The above uses.

Citation Information

Patent Citations

  • Stable liquid pharmaceutical preparation

    CA3028238A1

  • Administration method of anti-tnfα antibody

    JP2005517629A

  • Multiple-variable dosing regimens for treating tnfα-related disorders

    JP2008502596A